Investigational Medicinal Products for the Inner Ear: Review of Clinical Trial Characteristics in ClinicalTrials.gov

Colleen G. Le Prell, PhD

Department of Speech, Language, and Hearing, School of Behavioral and Brain Sciences, University of Texas at Dallas, Richardson, Texas

Address for correspondence Colleen Le Prell, PhD, colleen.leprell@utdallas.edu

J Am Acad Audiol 2021;32:670–694.

Abstract

Background The previous 30 years have provided information on the mechanisms of cell death in the inner ear after noise exposure, ototoxic drug injury, and during aging, and clinical trials have emerged for all of these acquired forms of hearing loss. Sudden hearing loss is less well understood, but restoration of hearing after sudden hearing loss is also a long-standing drug target, typically using steroids as an intervention but with other agents of interest as well.

Purpose The purpose of this review was to describe the state of the science regarding clinical testing of investigational medicinal products for the inner ear with respect to treatment or prevention of acquired hearing loss.

Data Collection and Analysis Comprehensive search and summary of clinical trials listed in the National Library of Medicine (www.ClinicalTrials.gov) database identified 61 clinical trials.

Results Study phase, status, intervention, and primary, secondary, and other outcomes are summarized for studies assessing prevention of noise-induced hearing loss, prevention of drug-induced hearing loss, treatment of stable sensorineural hearing loss, and treatment of sudden sensorineural hearing loss.

Conclusion This review provides a comprehensive summary of the state of the science with respect to investigational medicinal products for the inner ear evaluated in human clinical trials, and the current challenges for the field.

Keywords
- otoacoustic emissions
- clinical trial
- ototoxicity
- noise induced hearing loss
- investigational medicinal product
- sensorineural hearing loss

Interests in otopathology underlying noise-induced hearing loss (NIHL), drug-induced hearing loss (DIHL), and age-related hearing loss (ARHL) are longstanding, dating back to at least the 1950’s (for historic review, see 1–3). Much of this literature shows outer hair cell (OHC) loss to be commonly associated with NIHL, DIHL, and ARHL. With advances in microscopy, molecular biology, and biochemistry, understanding of acquired hearing loss accelerated over the past 30 years, resulting in detailed insights into the cellular and molecular events associated with acquired hearing loss.4 More recent reports have shown synapses between the inner hair cells (IHCs) and their auditory nerve fiber (ANF) targets to be highly vulnerable after noise-induced temporary threshold shift (TTS), with slow degeneration of the ANF population subsequent to synapse loss.5 These findings have stimulated interest in functional deficits associated with specific synaptic and/or hair-cell based otopathologies.6–8

received February 22, 2021
accepted after revision July 21, 2020

DOI https://doi.org/10.1055/s-0041-1735522.
ISSN 1050-0545.

© 2022. American Academy of Audiology. All rights reserved.
This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical Publishers, Inc., 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
The increasing understanding of mechanisms of NIHL, DIHL, and ARHL, has also driven expansive pre-clinical efforts to identify potential medicinal products for the inner ear, including otoprotective agents (delivered prior to injury/before the onset of hearing loss) and therapeutic treatments (delivered post injury/after the onset of hearing loss). Successful identification of possible medicinal products for the inner ear in animal models has supported the development and conduct of human clinical trials. There are multiple review papers, described next, that capture the systematic transition from work in animals to work in humans as the state of the science has progressed.

For those with interests in the role of oxidative stress and other biochemical events in acquired hearing loss, reviews from a variety of laboratories provide unique approaches and diverse insights into NIHL and DIHL prevention. Henderson et al.\(^9\) for example, provides a highly readable tutorial on the roles of oxidative stress and caspase activation in noise-induced apoptosis. Le Prell et al.\(^10\) provides comprehensive technical description of the cascade of biochemical reactions leading to cell death including not only oxidative stress but also the activation of other biochemical events leading to cell death, and includes discussion of the constriction of the cochlear blood supply (vasoconstriction) occurring as a result of oxidative stress. Abi-Hachem et al.\(^11\) expand on earlier reviews by noting overlapping protection for a variety of agents against NIHL and DIHL, and providing detailed discussion of the cytokine pathway, in which tumor necrosis factor alpha (TNF-\(\alpha\)) activates the mitogen-activated protein kinase/c-Jun N-terminal kinase (MAPK/JNK) signaling cascade and the nuclear factor kappa B (NFkB) signaling pathway, ultimately activating the caspase cascade and resulting in cell death. Poirrier et al.\(^12\) is helpful in providing additional information about the animal models used in studies on NIHL and DIHL otoprotection and provides brief review of the role of oxidative stress in ARHL.

Oishi and Schacht\(^13\) briefly summarized the animal literature and expanded on earlier reviews with concise identification of agents investigated in early human clinical trials. Information about the subset of agents entering clinical testing at that time (N-acetylcysteine (NAC), D-methionine, Ebselen, dietary micronutrients) was expanded in the review by Le Prell and Bao,\(^14\) which provides detailed description of both the extent of noise-induced permanent threshold shift (PTS) in control animals and relative reductions in PTS in animals treated with specific otoprotective agents. Evolution in the literature can be detected in the reviews by Le et al.\(^15\) and Sha and Schacht,\(^16\) which discuss not only antioxidants and the anti-inflammatory effects of corticosteroids, but also the potential that neurotrophic factors may restore the ribbon synapses connecting the IHCs to the ANFs.

Several recent reviews have focused on human clinical trials, and, more specifically, the trials listed on ClinicalTrials.gov; lists of clinical trial ID numbers can be found for both DIHL otoprotection\(^17\) and NIHL otoprotection.\(^18\) Not all clinical trials are listed in the largely U.S.-based ClinicalTrials.gov database. There are other national and international clinical trial registries, including for example the EU Clinical Trials Register (EU-CTR). Therefore, the review by Schilder et al.\(^19\) is particularly important as it provides a comprehensive summary of all drugs under commercial development for auditory indications regardless of what phase of development they were in at the time of the review. That review identifies 43 biotechnology and pharmaceutical companies developing a variety of agents with diverse mechanisms of action, with some agents in pre-clinical testing (i.e., under investigation in animal models) and others being tested in humans for either safety or efficacy.

Also worth note is the recent review of ARHL mechanisms and possible pharmacotherapies including antioxidants, anti-inflammatories, caspase inhibitors, and neurotrophins.\(^20\) Insights into the quality of the various reports on human otoprotection can be obtained from the systematic review by Gupta et al.\(^21\) which conformed with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Gupta et al.\(^21\) concluded that meta-analysis is not currently possible given the heterogeneity in methodologies and agents of interest, a finding that parallels earlier discussion of NIHL otoprotection research, with Le Prell and Miller\(^22\) noting the challenges comparing relative efficacy of different agents tested in animal models based on the variation across study protocols.

Recent reviews expand on the variation across study protocols, with detailed discussions of NIHL otoprotection research paradigms in mice,\(^23\) rats,\(^24,25\) guinea pigs,\(^26\) and chinchillas,\(^27,28\) using impulse noise,\(^29\) octave band noise,\(^30\) or blast.\(^31\) The variation observed in the design of preclinical studies is paralleled by variation in the design of human clinical trials. A variety of review papers highlight the diverse clinical trial paradigms used in NIHL otoprotection that have emerged over time, with widely varying participant noise exposure\(^32\) and diverse study outcomes to be considered.\(^33–36\) The problem of NIHL and difficulties accessing populations in which human NIHL otoprotection or treatment can be both reliably and ethically investigated has been a topic of recent discussion for Service members,\(^37\) musicians and other performing artists,\(^38\) and workers exposed to occupational noise.\(^39,40\)

Within human DIHL research, recent detailed reviews have addressed clinical trials listed in ClinicalTrials.gov,\(^17,41\) and strategies for measuring DIHL.\(^42\) Significant ototoxic change (SOC) is defined by the American Speech-Language-Hearing Association (ASHA) and the American Academy of Audiology (AAA) as \(\geq 20\) dB shift at any one test frequency, \(\geq 10\) dB shift at any two consecutive test frequencies, or loss of response at 3 consecutive frequencies where a response was obtained at baseline.\(^43,44\) However, there are multiple other strategies for grading ototoxicity including for example Common Terminology Criteria for Adverse Events (CTCAE) published by the National Cancer Center, the TUNE grading scale, and the Brock, Chang, and International Society of Pediatric Oncology (SIOP) grading scales which are more commonly used for pediatric patients.\(^41,45,46\)

Despite the numerous reviews and discussions of investigational medicinal products for the inner ear (i.e., studies seeking evidence that a drug will prevent or treat NIHL, DIHL,
or ARHL), there is a major gap in the literature with no systematic summary of clinical trial characteristics across these auditory indications. The lack of data with respect to the primary, secondary, and other outcomes in human clinical trials evaluating investigational medicinal products for the inner ear is concerning as it is difficult to compare the potential efficacy of different agents when primary outcomes vary from trial to trial and secondary outcomes are even more diverse. The discussion by Vetter and Mascha is focused on anesthesiology rather than audiology, but their warnings regarding the importance of outcome selection within clinical trials applies across disciplines.

In the United States (U.S.), clinical trials are conducted under the oversight of the U.S. Food and Drug Administration (FDA). Within the FDA, the Center for Drug Evaluation and Research (CDER) oversees drug developers’ plans for manufacturing and testing new drugs via the Investigational New Drug (IND) application process. As part of this process, investigators describe the study outcomes selected to determine safety and efficacy of the drug that is under investigation. The IND and its review are confidential, as is CDER’s later review of completed reports to evaluate collected data, assess relative benefits and risks, and make decisions regarding labeling based on the clinical significance of the observed health benefits. Despite the confidentiality of the submissions to the FDA, studies meeting specific criteria related to U.S. data collection and/or U.S. drug manufacturing are required to be publicly disclosed via listing in the ClinicalTrials.gov database, per 42 CFR Part 11.

In addition to the rules for listing of clinical trials, 42 CFR Part 11 provides rules regarding the reporting of clinical trials. Results are generally required to be submitted no later than 1 year after the study’s primary completion date. However, there are several exceptions to this rule including delays allowed under certain conditions (such as seeking approval, licensing, or clearance of a new use for the drug, biological, or device product). Failure to report results can result in pursuit of civil monetary penalties by the FDA, and it is possible that current and future grant funds from the NIH may not be released if reporting requirements are not met. Rules, exceptions, and penalties are specified in 42 CFR Part 11.

Requirements for registration have at least in part been determined by concern that studies that are neither listed on a clinical trial repository nor published in the peer-reviewed literature could in effect be “hidden” from the scientific community with negative or other results not publicly disclosed. The International Committee of Medical Journal Editors (ICMJE) therefore recommends that journal editors require registration of clinical trials in a public trial registry at or before the time of first patient enrollment as a condition of consideration for publication and many journals are complying with this guidance.

While all studies allowed to proceed under the FDA’s IND process must be listed in the ClinicalTrials.gov database, not all studies listed on ClinicalTrials.gov are conducted under an IND. As per the disclaimer on the ClinicalTrials.gov website, “ClinicalTrials.gov, a resource provided by the U.S. National Library of Medicine (NLM), is a registry and results information database of clinical research studies sponsored or funded by a broad range of public and private organizations around the world. Not all studies listed on ClinicalTrials.gov are funded by the National Institutes of Health (NIH) or other agencies of the U.S. Federal Government. Not all listed studies are regulated and/or reviewed by the U.S. Food and Drug Administration or other governmental entities. Information on ClinicalTrials.gov is provided by study sponsors and investigators, and they are responsible for ensuring that the studies follow all applicable laws and regulations.”

Despite the limitation that the ClinicalTrials.gov database is not limited to studies completed under the oversight of the FDA, ClinicalTrials.gov is the best search tool currently available as there is no database listing only the trials reviewed by the FDA. None of the reviews identified in the comments above have systematically summarized study phase, status, population, outcomes, etc., within or across indications (NIHL, DIHL, ARHL, etc.). A systematic search of ClinicalTrials.gov listings was therefore performed to obtain current and complete information about clinical trials evaluating investigational medicinal products for the inner ear.

Methods

Clinical trials evaluating NIHL otoprotection were identified using search terms including “noise-induced hearing loss,” “NIHL,” “permanent threshold shift,” “noise induced auditory threshold shift,” “temporary threshold shift,” and “temporary auditory threshold shift.” The search process was started December 29, 2020 with final terms searched on February 21, 2021. For each of the returned results within ClinicalTrials.gov, the study record was opened and reviewed to determine if it met the inclusion criteria (use of an investigational medicinal product for prevention of NIHL). Studies that did not include an investigational medicinal product and/or did not evaluate NIHL prevention were excluded from further review. For those studies that met the inclusion criteria, Study ID (the ClinicalTrials.gov record number), study phase (as listed in the study record) and study status (as listed in the study record) were entered into Table 1. Age, hearing, health-related inclusion criteria, information about sound exposure and information about the investigational medicinal product were extracted from the ClinicalTrials.gov records and entered into Table 1. Finally, primary, secondary, and other outcomes were entered. Within ClinicalTrials.gov, the study sponsor specifies the category for each outcome. Subsequent to the database search, the search results captured in Table 1 were cross-checked against the lists of studies identified in previous reviews to assure that no previously identified listings had been missed.

Clinical trials evaluating DIHL otoprotection were searched on February 16, 2021 using the search terms “otoxicity,” “otoxic hearing loss,” and “otoprotection,” as well as the combination term “cancer and hearing loss.” For each of the returned results within ClinicalTrials.gov, the
| Study ID  | Study phase; study status | Inclusion criteria | Intervention | Primary outcomes | Secondary outcomes | Other outcomes |
|----------|--------------------------|-------------------|--------------|------------------|-------------------|---------------|
| 50 NCT00552786 | Completed; has results | 25–65 yo, male Worker in steel industry Daily workplace noise exposure | N-acetylcysteine (NAC, 600 mg, twice daily for two wks) | Average threshold shift at 3, 4, and 6 kHz immediately post-work shift on 14th day of dosing | Average DPOAE threshold change at 3, 4, and 6 kHz immediately post-work shift on 14th day of dosing | N/A |
| 51 NCT00808470 | Completed; has results | 18–31 yo Type A tympanogram ≤25 dB HL, 0.25–8 kHz Air-bone gaps ≤10 dB Asymmetry ≤ 15 dB 4 hr pre-recorded music delivered by insert earphones | Vitamin C (500 mg), magnesium (315 mg), vitamin E (267 mg), β carotene (18 mg); 6 chewable tablets once daily for 4 days | Average threshold shift at 4 kHz in both ears 15 min post music | Threshold shift at individual frequencies from 0.25 to 8 kHz 15 min post music 2. Tinnitus Presence (Yes/No) | 1. DPOAE amplitude change 15 min post music and at later times 2. Threshold shift at individual frequencies from 0.25 to 8 kHz 1 hr 15 min post music and at later times |
| 52 NCT01444846 | Completed, results submitted | 18–31 yo Type A tympanogram ≤25 dB HL, 0.25–8 kHz Air-bone gaps ≤10 dB Asymmetry ≤ 15 dB Heart rate, blood pressure, respirations, temperature within normal limits upon medical examination 4 hr pre-recorded music delivered by insert earphones | Ebselen (SPI-1005 capsule, 200, 400, or 600 mg; twice daily for 4 days) | Post-sound exposure pure tone audiometry compared with baseline testing to determine group mean level hearing threshold shift | N/A | N/A |
| 53 NCT02257983 | Completed; no results posted | 18–30 yo Healthy adults Normal audiology exam 4 hr sound exposure | Vincerinone™ (EPI-743, capsule, 400 mg orally t.i.d. for 9 days) | Pure tone audiometry | Time to recovery following acute noise exposure | N/A |
| 54 NCT02903355 | Terminated; no results posted | 21–45 yo Normal tympanometry PTAS1 ≤40 dB HL Air-bone gaps ≤10 dB Drill Sergeant instructor trainees during and 22 days after their 11-day weapons training | D-methionine (oral liquid suspension, once daily for 18 days) | 1. Change in pure-tone thresholds measured by absolute change and frequency of STS at day 15–16 2. Change in pure-tone thresholds measured by absolute change and frequency of STS at day 22 | 1. Change in tinnitus loudness/annoyance at day 15–16 2. Change in tinnitus loudness/annoyance at day 22 3. Tympanometric change | N/A |
| 55 NCT02779192 | Not yet recruiting | 18–50 yo existing NIHL history of occupational or recreational noise exposure exposure to calibrated sound challenge | Ebselen (SPI-1005 capsule, 200 or 400 mg, twice daily for 7 days) | Reduction in incidence of STS post-exposure | Improvement on post-exposure word recognition score, using Words in Noise (WN) test | Adverse events due to study drug |
| 57 NCT02049073 | Withdrawn | 18–30 yo Good to excellent health Normal hearing 4 hr of pre-recorded music delivered by insert earphones | Zonisamide (pill, 100 or 200 mg either as single dose or once daily for 2 wks) | Pure tone hearing thresholds (particularly 2, 3, 4, and 6 kHz) 15-min post-exposure | 1. DPOAE 2. Tinnitus (THI) 3. Pure tone hearing thresholds 75-, 135-, and 195-min post-exposure | Recovery of hearing one-wk post-exposure |
| 57 NCT02049073 | Withdrawn | 18–30 yo Good to excellent health Normal hearing 4 hr pre-recorded music delivered by insert earphones | Methylprednisolone (pill, 32 mg or 64 mg single dose) | Pure tone hearing thresholds (particularly 2, 3, 4, and 6 kHz) 15-min post-exposure | 1. DPOAE 2. Tinnitus (THI) 3. Pure tone hearing thresholds 75-, 135-, and 195-min post-exposure | Recovery of hearing one-wk post-exposure |

(Continued)
A study record was opened and reviewed to determine if it met the inclusion criteria (use of an investigational medicinal product for prevention of DIHL). Studies that did not include an investigational medicinal product and/or did not evaluate DIHL prevention were excluded from further review. For those studies that met the inclusion criteria, Study ID (the ClinicalTrials.gov record number), study phase (as listed in the study record) and study status (as listed in the study record) were entered into Table 2. Age, hearing, and health-related inclusion criteria and information about planned therapy with chemotherapeutics or aminoglycoside antibiotics were extracted from the ClinicalTrials.gov records and entered into Table 2. Information about the investigational medicinal product and primary, secondary, and other outcomes were entered into Table 2. Subsequent to the database search, the search results were cross-checked against the lists of studies identified in previous reviews to assure that no previously identified listings had been missed.

Clinical trials evaluating drug benefits in patients with sensorineural hearing loss (SNHL) were searched on February 21, 2021 using the search terms "sensorineural hearing loss," "age-related hearing loss," "presbycusis," and "hearing in noise." While ARHL is of particular interest with respect to the large population that could benefit from potential prevention or treatment strategies, search terms were deliberately broad to capture not only ARHL but other SNHL studies that may share common otopathologies including sensory cell (OHC, IHC) loss, synaptic loss, and ANF degeneration. For each of the returned results within ClinicalTrials.gov, the study record was opened and reviewed to determine if it met the inclusion criteria (use of an investigational medicinal product for treatment or prevention of SNHL). Studies that did not include an investigational medicinal product and/or did not evaluate treatment or prevention of SNHL were excluded from further review. For those studies that met the inclusion criteria, Study ID (the ClinicalTrials.gov record number), study phase (as listed in the study record) and study status (as listed in the study record) were entered into either Table 3 or Table 4. Table 3 includes studies investigating treatment of patients with chronic (stable) SNHL whereas Table 4 includes studies investigating treatment of acute (sudden) SNHL with the goal of reducing or preventing permanent SNHL. Age, hearing, and health-related inclusion criteria were extracted from the ClinicalTrials.gov records and entered into Table 3 or 4 as appropriate for each record. Information about the investigational medicinal product and primary, secondary, and other outcomes were also entered. Because the original records were reported as posted, labels for sudden hearing loss, sudden sensorineural hearing loss (SSHL or SSNHL), and idiopathic sudden sensorineural hearing loss (ISSNHL) may appear to be used inconsistently in the data tables. Rather than revise study terminology for consistency within the data table, the study information has been reported as entered in ClinicalTrials.gov.

Taken together, the information that was extracted from all clinical trial records identified through the above search
| Study ID; Study phase; study Status | Inclusion criteria | Intervention | Primary outcomes | Secondary outcomes | Other outcomes |
|-----------------------------------|-------------------|--------------|------------------|-------------------|--------------|
| 63 NCT0716976 3 Completed, has results | 1–18 yo Newly diagnosed with germ cell tumor, hepatoblastoma, medulloblastoma, neuroblastoma, osteosarcoma, or other malignancy Planning to receive chemotherapy including cumulative cisplatin dose ≥ 200 mg/m² with individual cisplatin doses to be infused over ≤ 6 hr | Sodium thiosulfate (16 g/m² or 533 mg/kg for patients administered cisplatin on a per kg basis due to young age or small body; administered over 15 min beginning 6 hr after completion of each cisplatin infusion) | Rate of ASHA SOC | 1. Change in hearing at 0.5, 1, 2, 4, and 8 kHz 4 wks post cisplatin 2. Event free survival 4 yrs post enrollment 3. Overall survival 4 yrs post enrollment 4. Hearing loss 4 wks post cisplatin in genetic mutation subgroups | N/A |
| 61 NCT00477607 2 Completed; has results | ≥ 18 yo Diagnosis of cancer Able to provide reliable behavioral threshold Treatment with cisplatin | Alpha-lipoic acid (1200 mg once/daily) | Rate of ASHA SOC | 1. Maximum malondialdehyde (MDA) level increase 2. Maximum cumulative dose of cisplatin | N/A |
| 66 NCT01848457 2 Completed, has results | ≤ 30 yo Histological diagnosis of high-grade osteosarcoma Extremity or central axis primary tumor; localized or metastatic Hearing level threshold ≤ 25 dB at all frequencies in both ears Cisplatin and high-dose methotrexate | Pantoprazole (0.3 mg/kg i.v. as a loading dose followed by 1.3 mg/kg i.v. concurrent with cisplatin) | Change in urinary biomarkers of acute kidney injury | 1. Change in tumor volume 2. Validating urinary biomarkers 3. Tissue microarray 4. Bone specific alkaline phosphatase 5. Nutritional status 6. Patient reported outcome survey 7. Average hearing level over the range of 4 to 8 kHz | N/A |
| 65 NCT01372904 2 Completed, has results | ≥ 18 yo Neoplastic disease Treatment protocol includes cumulative cisplatin dose of at least 300 mg | Dexamethasone Phosphate (0.7 ml of 10 mg/ml solution delivered into middle ear via trans-tympanic injected) | Pure tone, speech, and impedance audiometry, and DPOAE testing | N/A | N/A |
| 62 NCT00652132 3 Completed, no results posted | 1 mo–18 yo Histologically confirmed newly diagnosed hepatoblastoma Patients receive cisplatin i.v. over 6 hr on day 1 then every 2 wks for 4 courses | Sodium thiosulfate (administered i.v. over 15 min beginning 6 hr after completion of each cisplatin infusion) | Hearing loss rated using Brock grading scale (end of trial treatment or 3.5 yrs, whichever is later) | 1. Response to preoperative chemotherapy 2. Complete resection 3. Complete remission 4. Event-free survival 5. Overall survival 6. Adverse drug reactions graded using CTCAE v 3.0 7. Long-term renal clearance 8. Feasibility of central audiology review (end of trial treatment or 3.5 yrs, whichever is later) | N/A |
| 69 NCT01271088 2/3 Completed, no results posted | 18–65 yo End-stage renal disease Continuous ambulatory peritoneal dialysis Treatment with vancomycin and/or amikacin for peritonitis | NAC (600 mg, twice daily) | Rate of ASHA SOC | N/A | N/A |
| 64 NCT01139281 2 Completed, no results posted | ≥ 18 yo Beginning treatment with cisplatin | Ginkgo Biloba Extract (GBE761, 120 mg twice daily) | DPOAE mean amplitude and SNR values at frequencies from 1 to 8 kHz | N/A | N/A |

(Continued)
| Study ID: | Study phase; study Status | Inclusion criteria | Intervention | Primary outcomes | Secondary outcomes | Other outcomes |
|-----------|--------------------------|-------------------|--------------|------------------|-------------------|---------------|
| NCT0003269 | Completed; no results posted | 19–80 yo; Confirmed diagnosis of advanced head and neck cancer or advanced lung cancer; Undergoing treatment with cisplatin, cyclophosphamide, and etoposide | Amifostine, i.v. | Duration of neutropenia | Incidence of nephrotoxicity | N/A |
| NCT0003269 | Completed; no results posted | 19–80 yo; Confirmed diagnosis of advanced head and neck cancer or advanced lung cancer; Undergoing treatment with cisplatin, cyclophosphamide, and etoposide | Amifostine, i.v. | Duration of neutropenia | Incidence of nephrotoxicity | N/A |
| NCT01131468 | Completed, no results posted | 18–70 yo; End-stage renal disease; Continuous ambulatory peritoneal dialysis; Treatment with vancomycin and/or amikacin for peritonitis | N/A (600 mg, twice daily) | Purpose of study is to measure prevention of hearing loss; primary outcome not specified | N/A | N/A |
| NCT03400709 | Completed, no results posted | ≥18 yo; Diagnosed with head and neck squamous cell carcinoma; Chemoradiotherapy including cisplatin | NAC (oral, before, during, and after cisplatin) | 1. HFPTA (6–16 kHz) at baseline 2. HFPTA up to 4th wk of chemoradiotherapy 3. HFPTA at study completion | N/A | N/A |
| NCT04226456 | Recruiting | ≥18 yo; Patients with a neoplastic disease to be treated with cisplatin, 70 to 100 mg/m² i.v. for 3 to 7 cycles, with or without radiotherapy | NAC (injection of 10% solution via trans-tympanic injection in both ears) | 1. Ototoxicity 6 mo after last injection, as defined by CTCAE 5.0 | 1. Ototoxicity 6 mo after last injection, as defined by Tone grading scale 2. Hearing quality of life 3. Tinnitus Handicap Index (THI) | N/A |
| NCT04541355 | Recruiting | ≥18 yo; Histologically or cytologically confirmed locoregionally advanced squamous cell carcinomas of mucosal surfaces of head and neck | Sodium thiosulfate (i.v. delivered over 1–2 hr 4–5 hrs post cisplatin) | Number of patients who successfully complete planned treatment | 1. Frequency of treatment related adverse events 2. Incidence of high-grade ototoxicity (change ≥2 grades on CTCAE v 5.0) | N/A |
| NCT00075387 | Recruiting | 18–75 yo; Histologically confirmed high-grade glioma | Sodium thiosulfate (i.v. over 15 min at 4 and 8 hr after carboplatin) | Rate of platelet toxicities | 1. Number of dose reductions and transfusions 2. Tumor response 3. Time to response 4. Time to disease progression 5. Granulocyte count 6. Erythrocyte counts 7. Change in hearing at 4 and 8 kHz, and from 9 to 16 kHz, including time to ASHA SOC 8. Quality of life | N/A |
| NCT04291209 | Recruiting | ≥18 yo; Advanced stage head and neck cancer; High dose systemic cisplatin (100 mg/m²) with concurrent radiation therapy as part of their curative intent treatment | NAC (intra-tympanic) | Determination of safe and tolerable dose range for intra-tympanic NAC 2. Rate of hearing loss, defined as 10 dB shift at 3-contiguous frequencies | Hearing discrimination, subjective tinnitus, otoacoustic emission, speech spatial and quality of hearing | N/A |
| NCT00983398 | Recruiting | 18–45 yo; Histologically confirmed CNS embryonal tumor or germ cell tumor; Regimen including mannitol IA over 30 sec, melphalan IA over 10 min, carboplatin IA | Sodium thiosulfate i.v. over 15 min at 4 and 8 hr after carboplatin | 1. Maximum tolerated dose 2. Response rate | 1. Progression free survival 2. Overall survival rate 3. Change in neurocognitive assessment score 4. Ototoxicity up to 30 days post | N/A |
| Study ID: Study phase; study Status | Inclusion criteria | Intervention | Primary outcomes | Secondary outcomes | Other outcomes |
|-----------------------------------|-------------------|--------------|------------------|-------------------|---------------|
| NCT04262336 Recruiting          | ≥18 yo Ability to communicate | Sodium thiosulfate (DB-020, 12% or 25%, delivered via intra-tympanic injection) | Number of patients with treatment-emergent adverse events and/or abnormal changes from baseline in clinical laboratory abnormalities and/or vital signs and/or ECG assessments | 1. Incidence of ASHA SOC 28 days after last dose 2. Change in threshold at frequencies from 0.25 to 16kHz 3. Change in Tinnitus Functional Index (TFI) 4. Change in DPOAE amplitude from 1–4 kHz 5. Change on Words-in-Noise (WIN) test score 6. Change in Hearing Handicap Inventory for Adults (HHIA) 7. Plasma concentration of DB-020 prior to cisplatin 8. Maximum observed cisplatin plasma concentration (Cmax) 9. Area under the cisplatin plasma concentration-time curve (AUC 0-inf) 10. Time to reach maximum observed cisplatin plasma concentration (tmax) 11. Half-life (t1/2) of cisplatin plasma concentrations | N/A |
| NCT02094625 Recruiting          | 1–21 yo New diagnosis of a localized malignancy Planned treatment course to include at least two cycles of cisplatin Total cumulative dose of planned cisplatin must be >200mg/m² (or 6.67 mg/kg equivalent for infants requiring weight-based dosing) | NAC (225, 300, or 450mg/kg i.v., administered over ~60 min starting 4 hr after completion of cisplatin chemotherapy) | NAC target serum level immediately after first NAC dose | 1. Adverse events during NAC infusion 2. NAC serum level pre-cisplatin, post-cisplatin, and 4 hr post NAC 3. Hearing assessment up to 40 wks from start of cisplatin 4. Renal toxicity 5. Response of tumor to treatment 6. Effect of genotype on hearing loss and otoprotection (glutathione polymorphisms) 7. Glutathione serum levels pre-cisplatin, post-cisplatin, immed post NAC, and 4 hr post NAC | N/A |
| NCT02819856 Enrolling by invitation | ≥18 yo Ability to perform behavioral tests Cystic fibrosis patients about to receive IV tobramycin for acute pulmonary exacerbation | Ebselen (SPI-1005 capsule, 200, 400, or 600mg, twice daily for 21 days) | 1. Number of participants with sensorineural hearing loss 2. DPOAE threshold shift in extended high frequency range 3. Change in WIN score 4. Changes in TFI 5. Vertigo symptom scale 6. Lung function | 1. Pharmacogenomics (gene expression for Nrf2, glutathione peroxidase-1, hemeoxygenase-1, and thioredoxin class of redox proteins) 2. Pharmacodynamics (level of glutathione, cysteine, and cystine) | N/A |

(Continued)
| Study ID; Study phase; study Status | Inclusion criteria | Intervention | Primary outcomes | Secondary outcomes | Other outcomes |
|-----------------------------------|-------------------|--------------|-----------------|-------------------|---------------|
| 81 NCT02997189 2 Terminated (based on efficacy results from another study) | 6 mo – 21 yo Diagnosed with neuroblastoma, hepatoblastoma, osteosarcoma or extracranial germ cell tumors and has not been previously treated with cisplatin or carboplatin ≤ 20dB HL from 2–8kHz in both ears Scheduled to receive a chemotherapy regimen that includes a cumulative cisplatin dose of ≥ 200 mg/m². | Dexamethasone (OTO-104, 12mg dexamethasone delivered via intratympanic injection) | 7. Plasma ebselen and major metabolites, trough levels | Feasibility assessed via questionnaire | N/A |
| 79 NCT01369641 N/A Terminated, poor accrual | ≥18 yo Cisplatin in the dose range of 80–120mg/m² | Sodium thiosulfate eardrops administered through the tympanic membrane via pressure equalization tubes | Degree or incidence of hearing loss using pure tone and speech audiometry, and DPOAE at 3, 6, and 12 wks, and every 6 mo thereafter for up to one yr | N/A | N/A |
| 80 NCT02281006 2 Terminated, poor accrual | ≥18 yo Newly-diagnosed locally-advanced (stage III or IV) squamous cell carcinoma of the mouth, oropharynx, hypopharynx, or larynx Scheduled to be treated with cisplatin 100mg/m² 3 times | Sodium thiosulfate gel (0.1 ml of Seacalphyx + Healon gel placed on round window via trans-tympanic injection) | Permanent threshold shift at 9, 10, 12.5 and 14 kHz, one mo post-cisplatin | 1. DPOAE recordings 2. Permanent threshold shift at 9, 10, 12.5 and 14 kHz, one mo and one yr post-cisplatin 3. Adverse effects of trans-tympanic injection | N/A |
| 78 NCT00074165 2 Terminated, lack of accrual; results posted | 18 mo - 75 yo Histologically confirmed primary CNS lymphoma Receive rituximab i.v. on day 1; on days 2 and 3: carboplatin intra-arterially over 10 min, cyclophosphamide i.v. over 10 min, and etoposide or etoposide phosphate i.v. over 10 min in conjunction with blood-brain barrier disruption | High-dose sodium thiosulfate i.v. over 15 min administered 4 and 8hr after carboplatin on days 2 and 3 | Complete response to chemotherapy regimen at 2 yrs | 1. Overall survival at 5 yrs 2. Progression-free survival at 5 yrs 3. Quality of life before treatment and every 3 mo 4. Ototoxicity assessed monthly during treatment 5. Complete blood count weekly during treatment | N/A |
| 84 NCT02382068 NA Withdrawn | ≥18 yo Planned cisplatin treatment >50mg/m² every 3–4 wks up to 7 cycles maximum | Dexamethosone (intra-tympanic injection) | DPOAE amplitude in conventional and high frequency ranges up to 3 mo post cisplatin | N/A | N/A |
| 82 NCT01138137 1 Withdrawn | 18–75 yo Histologically confirmed diagnosis of stage 3 or 4 epithelial ovarian or primary peritoneal carcinoma Paclitaxel IV, 135mg/m² (day 1) and IP cisplatin 100 mg/m² (day 2), followed by IV NAC (i.v., starting at 150mg/kg) infused over 30 min, starting 60min prior to each course of IP cisplatin with planned dose escalation for NAC | Determine the maximum tolerated dose and assess toxicity of NAC | 1. Tumor response 2. Incidence and severity of nephrotoxicity 3. Incidence and severity of hearing loss 4. Incidence and severity of hearing loss | 1. DPOAE amplitude in conventional and high frequency ranges up to 3 mo post cisplatin 2. ASHA SOC up to 3 mo post cisplatin | N/A |
| Study ID; Study phase; study Status | Inclusion criteria | Intervention | Primary outcomes | Secondary outcomes | Other outcomes |
|-----------------------------------|-------------------|--------------|-----------------|--------------------|---------------|
| NCT00584155 1 Withdrawn           | ≥18 yo Patients with cancer to be treated with cisplatin Must be expected to receive a minimum of 3 rounds of chemotherapy with a minimum cisplatin dose of 70 mg/m² | Lactated Ringer’s Solution with 0.03% ofloxacin (one dropper full delivered in ear canal, at start of chemotherapy, 30 min post chemotherapy, and hourly for 4 hr after chemotherapy) | Pre-treatment audiogram will be compared with the post treatment audiogram. | N/A | N/A |
| NCT01451853 2 Unknown            | 18–70 yo Histologically confirmed hematologic malignancies and adult solid tumors Undergoing treatment with platinum chemotherapy (cisplatin, carboplatin) | Ebselen (SPI-1005 capsule, 200, 400, or 600 mg, twice daily for 3 days for each cycle of chemotherapy) | Number of participants with adverse events | 1. Incidence and severity of hearing loss 2. Incidence and severity of tinnitus | N/A |
| NCT02241876 4 Unknown            | 18–80 yo Head and neck cancer Undergoing anticancer treatment including three cycles of cisplatin (80 to 100 mg/m²) plus radiotherapy | NAC [600 mg in 15 ml, administered once a day; during 7 days in each cycle (2 days before chemotherapy, on the day of chemotherapy, and 4 days after chemotherapy)] | 1. Hematologic, nephro, and hepatoxicity: 120 hr post-dose and 20 days post-dose 2. Gastrointestinal toxicity: 1 day and 240 hr post-dose 3. Ototoxic hearing loss: 1 day and 30 days post treatment 4. Nephrotoxicity: 1 day and 30 days post treatment | 1. Quality of life: 1, 2, 22, and 43 days post treatment 2. Cellular and plasma oxidative stress biomarkers: 120 hr and 20 days post-dose 3. Effectiveness of anticancer therapy: 1 and 30 days post treatment | N/A |
| NCT01108601 1/2 Unknown          | ≥15 yo Patients undergoing platinum-based chemotherapy | Lactated Ringer’s Solution with 0.03% ciprofloxacin (four drops delivered into ear canal twice a day during chemotherapy) | Pre-treatment audiogram will be compared with post-chemotherapy treatment audiogram for up to four yrs | DPOAEs | N/A |
| NCT01285674 N/A Unknown          | 18–90 yo Patients who are candidates for cisplatin treatment | Methylprednisol (intra-tympanic injection of 0.5cc of 4.5mg/cc; one injection per ear before each of 3 cisplatin treatments) | Change in hearing assessed by behavioral hearing test and otoacoustic emissions, -1 mo after first treatment | Appearance or worsening of tinnitus 1 mo post treatment | N/A |
| NCT00578760 N/A Unknown          | ≥18 yo Normal otoscopic examination Undergoing cisplatin treatment for germ-cell, bladder, or head and neck malignancy | Aspirin (325 mg daily orally during course of chemotherapy) | Hearing loss after chemotherapy | Hearing loss and tinnitus questionnaires after cisplatin treatment | N/A |
| NCT04132882 Compassionate Use Program Available | 1 mo – 18 yo Standard-risk hepatoblastoma Receiving cisplatin | Sodium thiosulfate (i.v. 80 mg/ml) | Any clinical assessments, physical examinations, and dosage changes will be determined by the treating physician as per local standard medical practice; all serious adverse events and related non-serious adverse events will be reported | N/A | N/A |

Abbreviations: ASHA SOC, Significant Ototoxic Change as defined by the American Speech-Language Hearing Association; AUC, area under the curve; Cmax, maximum observed plasma concentration; CNS, central nervous system; CTCAE, Common Terminology Criteria for Adverse Events; dB, decibel; dB HL, decibels hearing level; DPOAE, distortion product otoacoustic emission; ECG, electrocardiogram; g, gram; HFPTA, high-frequency pure-tone threshold average; hr, hour; i.v., intravenous; kg, kilogram; kHz, kilohertz; month, mo; m², meter squared; MDA, malondialdehyde; mg, milligram; min, minutes; ml, milliliter; N/A, not available; NAC, N-acetylcysteine; Nrf2, nuclear factor erythroid 2-related factor 2; sec, second; SIOP, International Society of Pediatric Oncology; SNR, signal to noise ratio; t1/2, half-life of plasma concentration; TFI, Tinnitus Functional Index; Tmax, time to reach maximum plasma concentration; WIN, Words-in-Noise; wk, week; yo, years old.
process was systematically entered into data tables for categories including prevention of NIHL (Table 1), prevention of DIHL (Table 2), reduction in stable SNHL (Table 3), and treatment for acute SSNHL (Table 4). Studies that did not meet the eligibility criteria for inclusion in any of the above categories were excluded and are not discussed further in this report.

There was no effort to determine if completed studies were published within the peer-reviewed literature; however, if the ClinicalTrials.gov record included results, this was recorded as part of the study status. While the focus of this review is not the specific agents under evaluation, the interventions and their timing were extracted and provided in the data tables to allow comparisons of investigational medicinal products for the inner ear across the included indications of interest. Within each Table, completed trials with results are listed first, followed by completed trials that have not posted results, and then studies that are currently recruiting participants, terminated studies, studies that are not yet recruiting, studies that have been withdrawn, and studies with unknown status.

Results

NIHL Otoprotection

Nine clinical trials evaluating NIHL otoprotection were identified (see Table 1). The studies summarized in Table 1 include four completed clinical trials evaluating TTS otoprotection,50–53 one terminated clinical trial evaluating PTS otoprotection,54 one not yet recruiting clinical trial evaluating PTS otoprotection,55 one study with unknown status evaluating TTS otoprotection,56 and two withdrawn clinical trials (both listed under57). Two of the completed trials have posted results,50,51 one submitted results which have not yet been posted,52 and one has not submitted results.53 While the listings included one phase 3 clinical trial,54 the majority of the clinical trials were Phase 2. One trial was identified as Phase 157 and one trial was defined as “Phase Not Applicable”56.

Across NIHL otoprotection clinical trials, the audiogram served as the primary outcome with six studies using reduction in average threshold shift as the primary outcome (50–52, both studies listed under 57). In addition, one study assessed both reduction in average threshold shift and reduction in Significant Threshold Shift (STS) rate,59 and one study assessed STS reduction.55 STS was not explicitly defined in the two studies listing STS as a primary or co-primary outcome.54,55 Only one study included hearing measures under “Other Outcomes,” with the primary and secondary outcomes for that study being tinnitus loudness and tinnitus duration56; other outcomes included high frequency audiometry, speech-in-noise testing, and otoacoustic emissions, but audiometric testing within the conventional frequency range was not included as an outcome for that one study. Distortion product otoacoustic emissions (DPOAEs) were included as a secondary outcome in three studies (50, both studies listed under 57), and as an “other” outcome measure for a subset of participants in two studies.51,56 Tinnitus measures including the rate at which tinnitus was reported and the loudness and annoyance of tinnitus were also included as secondary outcome measures (51,24, both studies listed under 57). Hearing-in-noise will serve as a secondary outcome in the not yet recruiting clinical trial,55 and is planned for a subset of participants in the study with unknown status.56 Two additional clinical trials were added to ClinicalTrials.gov after the above review and analysis were completed and they are not captured within Table 1 or the above summary.58,59 Neither of these newly added clinical trials are recruiting yet; both will examine PTS prevention.

DIHL Otoprotection

Thirty clinical trials evaluating DIHL otoprotection and one compassionate use protocol were identified (see Table 2). The studies summarized in Table 2 include 10 completed clinical trials evaluating either prevention of cisplatin-induced60–67 or amikacin-induced68,69 hearing loss. Currently, five studies are recruiting participants receiving cisplatin,70–74 two studies are recruiting participants receiving carboplatin,75,76 and one study is recruiting participants receiving tobramycin using invited enrollment.77 Four clinical trials were terminated either as a consequence of poor accrual78–80 or based on the results of related studies81 and three studies were withdrawn for reasons including lack of funding,82 departure of the principal investigator from the study site,83 or with no reason provided.84 Five studies had unknown status.85–89 As noted above, one compassionate use protocol is also included in Table 2.90 A compassionate use protocol allows a patient with a serious or life-threatening disease to gain access to an investigational drug outside of clinical trials when there is no treatment available, the patient has not benefited from approved treatments, or the patient is not eligible for enrollment in clinical trials.

Four of the completed DIHL otoprotection trials have posted results.61,63,65,66 and six have not submitted results.60,62,64,67–69 While the listings included two phase 3 clinical trials62,63 the majority of the clinical trials were Phase 1,70,71,82,83 Phase 1/2,72,76,88 Phase 2,60,61,64–66,68,73,75,77,78,80,81,85 or Phase 2/3.69 Two clinical trials were identified as Phase 474,86 and five clinical trials were identified as “Phase Not Applicable”57,79,84,87,89.

The DIHL studies included some trials in which audiometric changes served as the primary outcome and some trials in which the primary outcomes were related to cisplatin or aminoglycoside antibiotic therapeutic outcomes (event free survival, overall survival) and protection against audiometric change was a secondary outcome (see Table 2). Event free survival refers to the length of time post-treatment that the patient remains free of symptoms; in the context of the studies in Table 2, event-free survival would specifically refer to the length of time post-chemotherapy that the patient remains free of cancer symptoms. Overall survival refers to the length of time that the patient remains alive after the start of treatment. In studies in which investigational medicinal products for the inner ear are combined with chemotherapeutics, inclusion of event-free survival and overall survival are used to assure the investigational
| Study ID | Study phase, study Status | Inclusion criteria | Intervention | Primary outcomes | Secondary outcomes | Other outcomes |
|----------|--------------------------|-------------------|--------------|-----------------|-------------------|----------------|
| 105 NCT02345031 | Completed, has results | 50–89 yo English speaking Difficulty hearing in noisy environment No recent middle ear disease Not a professional musician Not a current or recent user of hearing aids | AUT00063 (enhances activity at voltage-gated potassium channels; 600 mg, orally, once a day, for 4 wks) | QuickSin | 1. Adaptive test of temporal resolution 2. Safety and Tolerability 3. Pharmacokinetics | N/A |
| 102 NCT01267994 | 1/2 Completed, has results | 13–75 yo Bilateral sensorineural hearing loss with active decline in hearing in one ear No audiometric improvement with 28–30 days oral prednisone or other corticosteroid Enrollment within 14 days of completion of corticosteroid therapy | Anakinra (interleukin-1 receptor antagonist, 100 mg by s.c. injection for 84 consecutive days) | Improvement in hearing threshold and durability of improvement to 180 days | Number of serious adverse events | N/A |
| 100 NCT01518920 | 1 Completed, no results posted | 50–75 yo Current diagnosis of age-related sensorineural hearing loss in the range of 30–60 dB, averaged over 2 and 4 kHz in at least one ear Symmetric hearing loss Can read, speak and comprehend English | PF-04958242, (0.27 or 0.35 mg oral solution, two single doses) | Change in the average threshold at 2 and 4 kHz at 1-hr post dose | 1. Change in the average threshold at 2 and 4 kHz at 5 hr post dose 2. Change in Speech Discrimination Score at 1- and 5 hr post dose 3. Change in Speech in Noise Score at 1- and 5 hr post dose 4. Change in Tinnitus Severity Rating Scale at 1- and 5 hr post dose 5. Plasma concentration at 45 minute post dose and following endpoint assessments at 1- and 5 hr post dose | N/A |
| 97 NCT03616223 | 1/2 Completed, no results posted | 18–65 yo Stable sensorineural hearing loss (no changes >10 dB at any frequency for >6 mos) Medical history consistent with hearing loss being caused by noise exposure or sudden sensorineural hearing loss | FX-322 (single intra-tympanic hydrogel injection; low dose or high dose) | Number of participants with treatment related adverse events, to day 15 | Time concentration of FX-322 in plasma within the first 24 hrs | N/A |
| 99 NCT02951715 | N/A Completed, no results posted | 20–80 yo Bilateral NIHL audiogram 4 kHz > 25 dB HL 10 dB notch at 4 or 6 kHz | Zinc gluconate (Zinga 78 mg, 10 mg elemental zinc), two tablets twice per day (40 mg elemental Zinc per day) | 1. THI 2. Serum Zinc level | 1. Pure tone audiometry 2. Speech discrimination 3. DPOAE SNR > 6 dB 4. Tinnitus pitch match 5. Tinnitus loudness match 6. Tinnitus loudness relative to threshold (dB SL) | N/A |
| 101 NCT04601909 | Active, not recruiting | 66–85 yo Documented medical history consistent with age-related sensorineural hearing loss Pure tone average of 26–70 dB at 0.5, 1, 2, and 4 kHz Ability to communicate well with the investigator | FX-322 (intra-tympanic hydrogel, single injection) | 1. Treatment related adverse events to 3 months 2. Safety – otoscopy to 3 months 3. Safety-tympanometry to 3 months 4. Columbia Suicide Severity Rating Scale to 3 months | 1. Word recognition in quiet (CNC word lists), to day 210 2. WIN/CNC word lists-in-noise to day 210 3. EHF audiometry to 3 mo 4. Tinnitus assessment to 3 mo | N/A |
| 98 NCT04120116 | 2 Active, not recruiting | 18–65 yo Stable sensorineural hearing loss (no changes >10 dB at any one frequency or >5 dB at any two contiguous frequencies from most recent audiogram to study screening) Medical history consistent with hearing loss being caused by noise exposure or sudden | FX-322 (intra-tympanic hydrogel; one, two, or four doses of active agent within 4 wks doses) | 1. Word recognition in quiet (CNC word lists), to day 210 2. WIN/CNC word lists-in-noise to day 210 3. Standard pure tone audiometry, to day 210 4. Systemic Safety, to day 210 | 1. EHF pure tone audiometry, to day 210 2. THI, to day 210 3. Hearing Handicap Inventory, to day 210 4. Hearing Screening Inventory, to day 210 | N/A |

(Continued)
| Study ID         | Description                                                                 | Intervention                                                                 | Inclusion criteria                                                                 | Other outcomes                                                                 |
|-----------------|------------------------------------------------------------------------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| NCT01186185     | Clinical trial for hearing improvement in idiopathic sudden sensorineural hearing loss | Olopatadine (oral antihistamine, 10 mg twice daily for 28 days)                 | Age ≤ 80 years, able to communicate well with the investigator, and willing to participate | Change in THI at 30 days and 1 year post treatment; Global cognitive protection (for a change of >3 points) |
| NCT04020975     | Clinical trial for hearing improvement in idiopathic sudden sensorineural hearing loss | Fludrocortisone (oral mineralocorticoid, 0.2 mg by mouth daily for 30 days)     | Age ≤ 80 years, able to communicate well with the investigator, and willing to participate | Change in THI at 30 days and 1 year post treatment; Global cognitive protection (for a change of >3 points) |
| NCT02414152     | Clinical trial for hearing improvement in idiopathic sudden sensorineural hearing loss | Anakinra (intravenous interleukin-1 receptor antagonist, 100 mg by s.c. injection) | Age ≤ 80 years, able to communicate well with the investigator, and willing to participate | Change in THI at 30 days and 1 year post treatment; Global cognitive protection (for a change of >3 points) |
| NCT04629664     | Clinical trial for hearing improvement in idiopathic sudden sensorineural hearing loss | FX-322 (oral N-methyl-d-aspartate receptor antagonist, 10 mg three times daily)  | Age ≤ 80 years, able to communicate well with the investigator, and willing to participate | Change in THI at 30 days and 1 year post treatment; Global cognitive protection (for a change of >3 points) |
| NCT04462198     | Clinical trial for hearing improvement in idiopathic sudden sensorineural hearing loss | PIPE-505 (oral acetylcholinesterase inhibitor, 0.2 mg by mouth daily for 30 days) | Age ≤ 80 years, able to communicate well with the investigator, and willing to participate | Change in THI at 30 days and 1 year post treatment; Global cognitive protection (for a change of >3 points) |
| NCT03101722     | Clinical trial for hearing improvement in idiopathic sudden sensorineural hearing loss | Fludrocortisone (oral mineralocorticoid, 0.2 mg by mouth daily for 30 days)     | Age ≤ 80 years, able to communicate well with the investigator, and willing to participate | Change in THI at 30 days and 1 year post treatment; Global cognitive protection (for a change of >3 points) |
| NA              | Clinical trial for hearing improvement in idiopathic sudden sensorineural hearing loss | Termination by investigator or sponsor                                         | Age ≤ 80 years, able to communicate well with the investigator, and willing to participate | Change in THI at 30 days and 1 year post treatment; Global cognitive protection (for a change of >3 points) |
| NCT01701722     | Clinical trial for hearing improvement in idiopathic sudden sensorineural hearing loss | Termination by investigator or sponsor                                         | Age ≤ 80 years, able to communicate well with the investigator, and willing to participate | Change in THI at 30 days and 1 year post treatment; Global cognitive protection (for a change of >3 points) |
| NCT01186185     | Clinical trial for hearing improvement in idiopathic sudden sensorineural hearing loss | Fludrocortisone (oral mineralocorticoid, 0.2 mg by mouth daily for 30 days)     | Age ≤ 80 years, able to communicate well with the investigator, and willing to participate | Change in THI at 30 days and 1 year post treatment; Global cognitive protection (for a change of >3 points) |
| NCT04020975     | Clinical trial for hearing improvement in idiopathic sudden sensorineural hearing loss | Fludrocortisone (oral mineralocorticoid, 0.2 mg by mouth daily for 30 days)     | Age ≤ 80 years, able to communicate well with the investigator, and willing to participate | Change in THI at 30 days and 1 year post treatment; Global cognitive protection (for a change of >3 points) |
| NCT02414152     | Clinical trial for hearing improvement in idiopathic sudden sensorineural hearing loss | Anakinra (intravenous interleukin-1 receptor antagonist, 100 mg by s.c. injection) | Age ≤ 80 years, able to communicate well with the investigator, and willing to participate | Change in THI at 30 days and 1 year post treatment; Global cognitive protection (for a change of >3 points) |
| NCT04629664     | Clinical trial for hearing improvement in idiopathic sudden sensorineural hearing loss | FX-322 (oral N-methyl-d-aspartate receptor antagonist, 10 mg three times daily)  | Age ≤ 80 years, able to communicate well with the investigator, and willing to participate | Change in THI at 30 days and 1 year post treatment; Global cognitive protection (for a change of >3 points) |
| NCT04462198     | Clinical trial for hearing improvement in idiopathic sudden sensorineural hearing loss | PIPE-505 (oral acetylcholinesterase inhibitor, 0.2 mg by mouth daily for 30 days) | Age ≤ 80 years, able to communicate well with the investigator, and willing to participate | Change in THI at 30 days and 1 year post treatment; Global cognitive protection (for a change of >3 points) |
| NCT03101722     | Clinical trial for hearing improvement in idiopathic sudden sensorineural hearing loss | Fludrocortisone (oral mineralocorticoid, 0.2 mg by mouth daily for 30 days)     | Age ≤ 80 years, able to communicate well with the investigator, and willing to participate | Change in THI at 30 days and 1 year post treatment; Global cognitive protection (for a change of >3 points) |
| NA              | Clinical trial for hearing improvement in idiopathic sudden sensorineural hearing loss | Termination by investigator or sponsor                                         | Age ≤ 80 years, able to communicate well with the investigator, and willing to participate | Change in THI at 30 days and 1 year post treatment; Global cognitive protection (for a change of >3 points) |
| NCT01701722     | Clinical trial for hearing improvement in idiopathic sudden sensorineural hearing loss | Termination by investigator or sponsor                                         | Age ≤ 80 years, able to communicate well with the investigator, and willing to participate | Change in THI at 30 days and 1 year post treatment; Global cognitive protection (for a change of >3 points) |

**Abbreviations:** BKB-SIN, Bamford-Kowal-Bench Speech-in-Noise test; CNC, consonant-nucleus-consonant; dB, decibel; dB HL, decibels hearing level; dB SL, dB sensation level; DPOAE, distortion product otoacoustic emission; EHF, extended high frequency; Hf, hour; Ht, time; kg, kilogram; kHz, kilohertz; mg, milligram; min, minutes; mo, month; N/A, not available; NIHL, noise-induced hearing loss; QuickSin, Quick Speech in Noise test; s.c., subcutaneous; SNR, signal to noise ratio; THI, Tinnitus Handicap Index; TFI, Tinnitus Functional Index; TH, Tinnitus Handicap Inventory; wk, week; yo, years old.
| Study ID | Inclusion criteria | Intervention | Primary outcomes | Secondary outcomes | Other outcomes |
|----------|--------------------|--------------|------------------|--------------------|---------------|
| 120 | ≥18 yo Unilateral idiopathic sensorineural hearing loss developing within 72 hour and occurring within past 14 days; Pure tone average at 0.5, 1, 2, and 4 kHz ≥ 50 dB HL in affected ear; Affected ear ≥ 30 dB worse than contralateral ear in at least one of the four frequencies | Methylprednisolone (four intra-tympanic injections over 2 wks; control condition is 19 days oral prednisolone) | Change in pure tone average at 0.5, 1, 2, and 4 kHz | N/A | N/A |
| 117 | ≥18 yo Unilateral idiopathic sensorineural hearing loss or acute acoustic trauma in one or both ears within past 96 hour | STR001-IT intratympanic gel injection with or without additional 12 wks treatment via STR001-ER oral tablets | Absolute hearing improvement after 12 wks | Percent of patients with complete hearing recovery after 12 wks | N/A |
| 121 | 18–75 yo Unilateral idiopathic sudden sensorineural hearing loss developing within 72 hour at least 12 days ago but no more than 21 days ago; Thresholds at 0.5, 1, 2, 3, and 4 kHz must be ≥ 50 dB HL for three frequencies, ≥ 60 dB HL for two frequencies, or ≥ 70 dB HL for one frequency within this range, or SRT ≥70 dB, or speech discrimination score ≤ 30% | Dexamethasone (continuous two-week intratympanic application, delivered to round window niche) | Pure tone audiometric threshold | 1. Word recognition 2. Tinnitus improvement 3. Adverse events | N/A |
| 115 | 18–65 yo Unilateral idiopathic sensorineural hearing loss developing within 72 hour prior to treatment; Mean hearing threshold ≥60 dB HL at 3 contiguous frequencies with largest hearing loss (“PTA frequencies”); Mean hearing loss ≥ 40 dB averaged across the PTA frequencies compared with contralateral ear, previous audiogram, or ISO 7029:2000 norms | AM-111 (0.4 mg/ml or 0.8 mg/ml given as single intra-tympanic injection) | Change in pure-tone-average threshold at 3 most affected frequencies at day 28 | N/A | N/A |
| 114 | 18–60 yo Unilateral acute sensorineural hearing loss within past 48 hour; Mean hearing loss ≥30 dB at 3 contiguous frequencies compared with contralateral ear | AM-111 (low dose or high dose as single intra-tympanic injection) | Change in pure-tone-average threshold at 3 most affected frequencies between day 0 and day 7 | Change in pure-tone-average threshold at 3 most affected frequencies between day 0 and days 3, 30, and 90 | N/A |
| 119 | 18–70 yo Unilateral idiopathic sudden sensorineural hearing loss ≥ 30 dB; Enrollment within 7 days after SSHL onset | Ancrod (also known as Viprinex; i.v. infusion on days 2, 4, 6) | Change in pure tone audiogram in the affected ear, at day 8 | Change in speech recognition in the affected ear, at day 8 | 1. Patient assessment of change in hearing on days 8, 30, and 90 2. Change in fibrinogen concentration 3. Change in biomarkers (Continued) |
| Study ID          | Study phase; study Status       | Inclusion criteria                                                                                     | Intervention                                                                                     | Primary outcomes                                                                                     | Secondary outcomes                          | Other outcomes |
|------------------|---------------------------------|--------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|---------------------------------------------|---------------|
| 118 NCT03603314  | 2/3 Recruiting                  | ≥18 yo Sudden hearing loss onset within 96 hours of first study drug intake Unilateral idiopathic SSHL or unilateral/bilateral acute acoustic trauma leading to SSHL | SENS-401 (5 HT3 antagonist, 29 or 43.5 mg dose, oral tablets, twice daily, for 4 wks)            | Change in pure tone audiometry PTA in affected ear from baseline to the end of treatment visit        | N/A                                         | N/A           |
| 122 NCT03255473  | 2 Recruiting                    | 18–80 yo Unilateral sudden sensorineural hearing loss (SSNHL) of 30 dB HL or greater over 3 continuous frequencies Participants report hearing loss occurred within 3 days Seen within six weeks of initial hearing loss Normal tympanometry | High-dose oral dexamethasone (control condition is standard of care, lower dose prednisolone)       | Change in pure tone threshold at 1 wk, 1 month, and 3 months                                         | 1. Change in word recognition               | N/A           |
|                  |                                 |                                                                                                       |                                                                                                | 2. Change in pure tone average threshold                                                              | 3. Frequency analysis for categories of hearing improvement                                        |               |
|                  |                                 |                                                                                                       |                                                                                                | 4. Percent analysis for categories of hearing improvement                                              |                                                            |               |
| 116 NCT02809118  | 3 Terminated (based on efficacy results from another study) | ≥18 yo Unilateral idiopathic sudden sensorineural hearing loss (ISSNHL) onset within 72 hour of study treatment Mean hearing threshold ≥60 dB HL at 3 contiguous frequencies with largest hearing loss ("PTA frequencies") Mean hearing loss ≥ 40 dB averaged across the PTA frequencies when compared with contralateral ear or preexisting audiogram collected within 2 years of the ISSNHL incident | AM-111 (0.4 or 0.8 mg/ml gel administered as a single intra-tympanic injection after topical anesthesia) | Change in pure-tone-average threshold at 3 most affected frequencies between day 0 and day 91 | Change in word recognition score between day 0 and day 91 | N/A           |

Abbreviations: dB, decibel; dB HL, decibels hearing level; hr, hour; ISSNHL, idiopathic sudden sensorineural hearing loss; i.v., intra-venous; kHz, kilohertz; mg, milligram; min, minutes; ml, milliliter; mo, month; N/A, not available; SSHL, sudden sensorineural hearing loss; SSNHL, sudden sensorineural hearing loss; wk, week; yo, years old.
product does not compromise the efficacy of the chemotherapeutic (see for example 91).

In the subset of DIHL studies in which audiogram-based measures served as secondary outcomes, the audiogram-based measures were nonetheless the primary strategy for evaluating otoprotection. The audiogram based measures serving as either primary or secondary outcomes in DIHL otoprotection trials included rate of ASHA-defined significant ototoxic change (i.e., ASHA SOC), 61,63,69,84 average threshold shift in the conventional frequency range, 66,83 and average threshold shift in the extended high frequency range. 67,90 Other audiogram based measures included deficits assessed using CTCAE ototoxicity grade, 73,74,76 Brocks grading categories, 62 and the SIOP-Boston ototoxicity scale. 81 One (terminated) study used DPOAE amplitude as the sole primary outcome measure, 79 and several studies included DPOAE amplitude shifts as a secondary outcome measure. 64,71,80,84 A few studies listed multiple audiometric measures as the primary outcome, such as pure tone and speech audiometry in combination with DPOAE testing. 65,79 or a combination of testing at conventional and extended high frequencies. 75,84 Other metrics including tinnitus, vertigo, words-in-noise, and/or the Hearing Handicap Inventory (first described by 92,93) were also included as secondary outcomes in some studies. 71,77 One less common primary outcome was a 10 dB shift at 3 contiguous frequencies. 72 Interestingly, there were a number of study listings in which the criteria for ototoxic change were not clearly defined. 60,68,70,78,82,85,86

### Stable SNHL Treatment

Eleven clinical trials evaluating drug benefits in patients with stable SNHL were identified (see Table 3). These studies included populations diagnosed with stable SNHL, 94–96 stable SNHL consistent with NIHL or previous (unresolved) SSNHL, 97,98 stable NIHL, 99 stable ARHL, 100,101 or SSNHL previously treated with but not responsive to steroids 102–104. In addition to the two studies investigating treatment for ARHL, 100,101 two additional studies listed in Table 3 specifically cited treatment of ARHL or presbycusis in the study title or the inclusion criteria for types of stable SNHL. 96,105 Thus, a total of four of the 13 studies listed within Table 3 specifically cited treatment of ARHL or presbycusis. Two additional studies listed in Table 3 recruited participants with difficulty hearing in noise. 105,106 These studies are included in Table 3 given that difficulty hearing in noise is widely hypothesized to be a consequence of damage to OHCs, IHCs, IHC/ANF synapses, ANFs, or a combination of these otopathologies. 8,107

Two of the completed stable SNHL trials have posted results, 102,105 and three have not submitted results. 97,99,100 The clinical trials were predominantly Phase 1 94,100,101,103 or Phase 1/2 95,97,102,104,106 with two Phase 2 clinical trials 98,105 and two trials identified as “Phase Not Applicable”. 96,99

The audiogram was the primary auditory outcome in the majority of studies listed in Table 3. The Quick Speech in Noise (QuickSin) test (described by 100) and the Words-in-Noise (WIN) test (described by 109,110) served as primary outcomes in one study each. 98,105 The Bench-Kowal-Bamford Speech in Noise Test (BKB-SIN) (described by 111,112) and the WIN served as a secondary outcome in one investigation each. 94,101 One study using speech-in-noise as a secondary outcome 100 and two studies using speech-in-noise as an “other” outcome 95,106 did not provide enough information to determine which speech-in-noise test was used. DPOAE testing was only included in one of these clinical trials 99 whereas tinnitus tests were included in six clinical trials. 94,96,98–101 Extended high frequency hearing was included in three clinical trials. 94,98,101 and auditory brainstem response was measured in two clinical trials. 95,100 Finally, patient-reported assessment of hearing was included in two clinical trials, 98,106 using tools such as the Hearing Handicap Inventory for Adults (HHIA), 92,93 Hearing Screening Inventory (HSI) (described by 113), or Patient Global Impression of Change (change in overall hearing status, ranging from very much worse (-3) to very much improved (+3)).

### Acute SSNHL Treatment

Nine clinical trials evaluating therapeutics for acute SSNHL are included in Table 4. Unlike the populations with stable SNHL listed in Table 3, the participants in studies listed in Table 4 were required to have developed their hearing loss over a short period of time. On the low end, they were required to present for SSNHL treatment from as short as 48,114 72,115,116 or 96,117,118 hours after the hearing loss occurred. On the high end, they were required to present for treatment within 7 days, 119 14 days, 120 12–21 days, 121 or six weeks 122 after the hearing loss occurred.

One completed trial has posted results, 120 and five have not submitted results. 114,115,117,119,121 While the listings are largely Phase 3 clinical trials, 115–117,120,121 Phase 1/2, 119 Phase 2, 114,122 and Phase 2/3 trials 118 were also noted. None of the clinical trials were identified as “Phase Not Applicable.”

In all identified acute SSNHL trials, the audiogram served as the primary outcome, with changes in pure tone thresholds being the primary outcome. Word recognition in quiet was included in four clinical trials, 116,119,121,122 and tinnitus measurement was included in one clinical trial, 121 DPOAEs, hearing-in-noise, and extended high frequency thresholds were not included as outcomes in any of these trials.

### Study Demographics

Interestingly, DIHL prevention research was more common than NIHL, stable SNHL, or SSNHL research with respect to completed research. The total number of DIHL otoprotection trials (n = 30) listed in ClinicalTrials.gov is roughly equivalent to the combined total for NIHL otoprotection trials (n = 9), stable SNHL (n = 13) treatment trials, and acute SSNHL (n = 9) treatment trials (see Table 5). Limiting the analysis to completed trials, more DIHL otoprotection trials (n = 10) listed in ClinicalTrials.gov have been completed than for NIHL otoprotection (n = 4), stable SNHL (n = 5) treatment, or acute SSNHL (n = 6) treatment; taken together, there are approximately twice as many DIHL trials completed relative to any other indication (see Table 5). While DIHL otoprotection...
trials (total and completed) are more numerous, DIHL, NIHL, and stable SNHL clinical trials are predominantly in Phase 1 or Phase 2 with 0-11% of trials being Phase 3 studies, whereas more than 50% (5/9) of the acute SSNHL trials are Phase 3 clinical trials.

Although DIHL studies are greater in number, they do not have higher success rates with respect to study completion. When the percent of completed clinical trials is expressed as a percent of the total listed trials, the current completion rate is around 40% for NIHL, DIHL, and stable SNHL trials, whereas almost 70% of the acute SSNHL trials have been completed (see Table 5). Of the completed studies, results have been submitted for 40-50% of NIHL, DIHL, and stable SNHL trials, whereas less than 20% of the completed acute SSNHL trials have

### Table 5 Comparison of clinical trial design, completion, and results submission rates across NIHL, DIHL, stable SNHL, and acute SSNHL studies

| Study Phase | NIHL (n = 9) | DIHL (n = 30) | SNHL (n = 13) | SSNHL (n = 9) |
|-------------|-------------|-------------|-------------|-------------|
| 1 (and ½)   | 1; 11%      | 7; 23%      | 9; 69%      | 1; 11%      |
| 2 (and ¾)   | 6; 67%      | 14; 47%     | 2; 15%      | 3; 33%      |
| 3           | 1; 11%      | 2; 7%       | 0           | 5; 56%      |
| 4           | 0           | 2; 7%       | 0           | 0           |
| NA          | 1; 11%      | 5; 17%      | 2; 15%      | 0           |
| Study Status| Completed, with results | 2; 22%      | 4; 13%      | 2; 15%      | 1; 11%      |
|             | Completed, no results | 2; 22%      | 6; 20%      | 3; 23%      | 5; 56%      |
|             | Percent of completed studies with results posted | 2/4 = 50%  | 4/10 = 40%  | 2/5 = 40%  | 1/6 = 17%  |
|             | Recruiting | 0           | 8; 27%      | 3; 23%      | 2; 22%      |
|             | Terminated | 1; 11%      | 4; 13%      | 2; 15%      | 1; 11%      |
|             | Not Yet Recruiting | 1; 11%      | 0           | 3; 23%      | 0           |
|             | Withdrawn   | 2; 22%      | 3; 10%      | 0           | 0           |
|             | Unknown     | 1; 11%      | 5; 17%      | 0           | 0           |
| Inclusion as Primary, Secondary, or Other Outcome | Average Shift | 7; 78%      | 14; 47%     | 8; 62%      | 9; 100%     |
|             | ASHA SOC    | 0           | 6; 20%      | 0           | 0           |
|             | CTCAE       | 0           | 3; 10%      | 0           | 0           |
|             | Brock       | 0           | 1; 3%       | 0           | 0           |
|             | Boston SOI | 0           | 1; 3%       | 0           | 0           |
|             | Tune        | 0           | 1; 3%       | 0           | 0           |
|             | Other STS   | 1; 11%      | 8; 27%      | 1; 8%       | 0           |
|             | DPOAE       | 5; 56%      | 10; 33%     | 1; 8%       | 0           |
|             | EHF         | 1; 11%      | 5; 17%      | 2; 15%      | 0           |
|             | Word Recognition | 0           | 2; 7%       | 6; 46%      | 4; 44%      |
|             | Hearing in Noise | 2; 22%      | 2; 7%       | 5; 38%      | 0           |
|             | Tinnitus    | 5; 56%      | 7; 23%      | 5; 38%      | 1; 11%      |
|             | Survey      | 0           | 6; 20%      | 2; 15%      | 1; 11%      |
|             | ABR         | 0           | 0           | 2; 15%      | 0           |
|             | Vertigo     | 0           | 1; 3%       | 0           | 0           |
| Method of Drug Delivery | Oral | 9; 100% | 9; 30% | 5; 38% | 2; 22% |
|             | Intra-tympanic/eardrop | 0           | 11; 37%     | 6; 46%      | 6; 67%      |
|             | Intra-venous | 0           | 10; 33%     | 0           | 1; 11%      |
|             | Sub-cutaneous | 0           | 0           | 2; 15%      | 0           |

Abbreviations: ABR, Auditory Brainstem Response; ASHA SOC, significant ototoxic change as defined by the American Speech-Language-Hearing Association; CTCAE, Common Terminology Criteria for Adverse Events as defined by the National Cancer Institute; DPOAE, Distortion Product Otoacoustic Emission; DIHL, drug-induced hearing loss; EHF, Extended High Frequency; NIHL, noise-induced hearing loss; SIOP, International Society of Pediatric Oncology; SNHL, sensorineural hearing loss; SSNHL, sudden sensorineural hearing loss; STS, Significant Threshold Shift.
results available. Taken together, it appears there are lower study completion rates for NIHL, DIHL, and stable SNHL than for acute SSNHL, but of the studies that are completed, results are somewhat more likely to be posted within ClinicalTrials.gov for NIHL, DIHL, and stable SNHL than for acute SSNHL studies.

Summary of Audiometric Outcomes
To facilitate comparisons across therapeutic targets (NIHL, DIHL, stable SNHL, acute SSNHL), summary data integrating information within the four clinical trial categories are provided in Table 5. With respect to clinical outcomes, there were notable differences across the different types of trials. For example, inclusion of average threshold shift as an outcome measure ranged from 47 to 100% across clinical trial categories. The use of this measure was lowest in the DIHL otoprotection category, at 47%, with 20% of trials monitoring the rate of ASHA SOC and 10% monitoring the rate of CTCAE adverse hearing events. None of the NIHL, stable SNHL, or acute SSNHL trials reported ASHA SOC, CTCAE adverse hearing events, or any of the other categorical ototoxicity monitoring scales as clinical trial outcomes. DPOAEs were monitored in about 33% of the DIHL and 56% of the NIHL trials, but they were largely absent from stable SNHL and acute SSNHL clinical trials. Conversely, word recognition in quiet was monitored in 44-46% of the stable SNHL and acute SSNHL clinical trials but none of the NIHL trials and only 7% of the DIHL trials. Interestingly, while DIHL is often accompanied by comorbidities including tinnitus and balance disorders, only 23% of DIHL clinical trials included tinnitus metrics whereas 56% of the NIHL otoprotection studies included tinnitus metrics.

Drug Delivery Methods
Differences across the method of drug delivery were also observed across trial categories, with fairly low (22-38%) rates of oral drug use in DIHL, stable SNHL, and acute SSNHL trials, but 100% oral administration in studies on NIHL prevention (see Table 5). Between 37 and 67% of DIHL, stable SNHL, and acute SSNHL trials used transtympanic drug administration, with relatively greater use in stable SNHL (46%) and acute SSNHL (67%) than DIHL (37%) trials. About 33% of the DIHL otoprotection studies administered the otoprotective agents intra-venously, presumably using i.v. lines already set up for the cisplatin or carboplatin infusions. None of the NIHL or stable SNHL trials used i.v. administration, and only one acute SSNHL trial used i.v. administration of the therapeutic agent. It is reasonable to infer that many of the individuals at risk for NIHL, such as Service members, employees working in loud industries, musicians and other performing artists, and others who are exposed to loud recreational sound would find an oral therapeutic easier to administer on a regular basis given recurring sound exposure, which may explain the bias towards oral therapeutics in NIHL otoprotection clinical trials.

Investigational Medicinal Products
Summary data for mechanism of drug administration is provided in Table 6. Review of Table 6 shows that some drugs have been tested using multiple methods of delivery. N-acetylcysteine (NAC), for example, has been delivered orally in six clinical trials (two NIHL, four DIHL), via intra-tympanic injection in two clinical trials (DIHL), and via intra-venous infusion in two clinical trials (DIHL). Similarly, methylprednisolone has been delivered orally in one clinical trial (NIHL) and via intra-tympanic injection in two clinical trials (one DIHL, one acute SSNHL). Finally, sodium thiosulfate has been delivered via intra-tympanic injection in two clinical trials (DIHL) and via intra-venous (i.v.) infusion in seven clinical trials (DIHL). Other drugs have shown less variation in their method of administration and their application for different targets within human clinical trials.

Discussion
The purpose of this review was to describe the state of the science regarding clinical testing of investigational medicinal products for the inner ear with respect to treatment or prevention of acquired hearing loss. Comprehensive search of clinical trials listed in the ClinicalTrials.gov database identified approximately 60 clinical trials assessing treatment or prevention of NIHL, DIHL, stable SNHL (including ARHL), or acute SSNHL. Clinical trials specifically targeting ARHL were a small subset, with only four clinical trials specifically identifying ARHL or presbycusis within the study title or the inclusion criteria. The study phase, status, intervention, and primary, secondary, and other outcomes were summarized for each study meeting inclusion criteria (Tables 1-4) with summary data provided across therapeutic indications in Tables 5 and 6. This review of completed and active clinical trials, as well as not yet active and discontinued trials, provides important insight into the state of the science.

It is encouraging to see active efforts to evaluate investigational medicinal products for the inner ear. As of the time of this review, a total of 13 clinical trials were actively recruiting participants and 4 were active but not yet recruiting. The majority of the trials actively recruiting were DIHL otoprotection studies (8/13, 62%) whereas the majority of the not yet recruiting trials (3/4, 75%) were stable SNHL treatment trials (see Table 5). Taken together, the most active clinical trial program appears to be DIHL otoprotection both with respect to the number of completed studies and the number of current studies but stable SNHL treatment studies are quickly emerging. This observed result is intriguing as NIHL otoprotection might be considered a potentially “easier” target than DIHL otoprotection because one does not need to worry about drug interactions that might occur if an otoprotective agent is delivered in parallel with and interacts with a drug (i.e., a chemotherapeutic or aminoglycoside antibiotic) with life-saving therapeutic benefits. As noted above, the inclusion of event-free survival and overall survival as the primary outcome in many clinicals investigating DIHL otoprotection in humans are done specifically because of this concern. On the other hand, participants in DIHL studies cannot avoid exposure to the ototoxin whereas participants in NIHL trials are often required to wear hearing
Table 6  Comparison of route of administration and specific drugs investigated across NIHL, DIHL, stable SNHL, and acute SSNHL studies

| Route of Administration | Oral Drug Administration | NIHL (n = 9) | DIHL (n = 30) | SNHL (n = 13) | SSNHL (n = 9) |
|-------------------------|---------------------------|--------------|---------------|---------------|---------------|
|                         |                            |              |               |               |               |
|                         | Alpha-Lipoic Acid          | 1            |               |               |               |
|                         | Aspirin                   | 1            |               |               |               |
|                         | AUTO00063                 | 1            |               |               |               |
|                         | Dexamethasone             | 1            |               |               |               |
|                         | D-methionine              | 1            |               |               |               |
|                         | Dietary Nutrient (ACEMg)  | 1            |               |               |               |
|                         | Fludrocortisone           | 1            |               |               |               |
|                         | EPI-743/Vincerinone       | 1            |               |               |               |
|                         | Ginkgo Biloba             | 1            |               |               |               |
|                         | Huperzine A               | 1            |               |               |               |
|                         | Methylprednisolone        | 1            |               |               |               |
|                         | N-acetylcysteine          | 2 4          |               |               |               |
|                         | PF-04958242               | 1            |               |               |               |
|                         | SENS-401                  | 1            |               |               |               |
|                         | SPI-1005/Ebselen          | 2 2          |               |               |               |
|                         | Zinc gluconate            | 1            |               |               |               |
|                         | Zonisamide                | 1            |               |               |               |
| Total                   |                            | 9; 100%      | 9; 30%        | 5; 38%        | 2; 22%        |
|                         | Intra-tympanic Drug Injection |            |               |               |               |
|                         | AM-111                    | 3            |               |               |               |
|                         | Dexamethasone             | 3 1          |               |               |               |
|                         | FX-322                    | 4            |               |               |               |
|                         | Methylprednisolone        | 1 1          |               |               |               |
|                         | N-acetylcysteine          | 2            |               |               |               |
|                         | OTO-413/BDNF              | 1            |               |               |               |
|                         | PIPE-505                  | 1            |               |               |               |
|                         | Sodium Thiosulfate        | 2            |               |               |               |
|                         | STR001-IT                 | 1            |               |               |               |
| Total                   |                            | 0            | 8; 27%        | 6; 46%        | 6; 67%        |
|                         | Eardrop Administration    |              |               |               |               |
|                         | Lactated Ringers          | 2            |               |               |               |
|                         | Sodium Thiosulfate        | 1            |               |               |               |
| Total                   |                            | 0            | 3; 10%        | 0             | 0             |
|                         | Intra-venous Drug Infusion |              |               |               |               |
|                         | Amifostine                | 1            |               |               |               |
|                         | Ancrod/Viprinex           | 1            |               |               |               |
|                         | N-acetylcysteine          | 2            |               |               |               |
|                         | Pantaprazole              | 1            |               |               |               |
|                         | Sodium Thiosulfate        | 7            |               |               |               |
| Total                   |                            | 0            | 10; 33%       | 0             | 1; 11%        |
|                         | Subcutaneous Drug Injection |              |               |               |               |
|                         | Anakinra/Kineret          | 2            |               |               |               |
| Total                   |                            | 0 2          | 10; 15%       | 0             | 0             |

Abbreviations: ACEMg, Combination of β-carotene, vitamins C and E, and magnesium; DIHL, drug-induced hearing loss; NIHL, noise-induced hearing loss; SNHL, sensorineural hearing loss; SSNHL, sudden sensorineural hearing loss.
protection devices (HPDs: earplugs, earmuffs) as part of hearing conservation programs and HPDs will prevent NIHL if they are consistently and correctly used by the participants. None of the studies listed in Table 1 provided specific information regarding sound exposure levels or HPD use even though this is an important factor to consider.

Significant efforts were made within this review to describe the various audiometric outcomes used across clinical trials with different therapeutic targets (NIHL, DIHL, stable SNHL (including ARHL), acute SSNHL), with noted variability both within and across clinical trials. Use of average threshold shift as an outcome measure (primary, secondary, or other) ranged from 47 to 100% across clinical trial categories. The use of this measure was lowest in the DIHL otoprotection category, at 47%. Instead of average threshold shift, DIHL studies very commonly used the rate of STS as primary, secondary, or other outcomes; 66% of the DIHL studies used rate of STS, with 20% of trials monitoring the rate of ASHA SOC (6/30), 10% monitoring the rate of CTCAE adverse hearing events (3/30), and 3% of trials each choosing Brock, Boston-SIOP, or Tune ototoxicity criteria. Given that both ASHA and AAA have published ototoxicity monitoring guidance based on the rate of STS, it is appropriate that rate of STS be considered the primary outcome in DIHL studies although comparisons across studies would be facilitated by use of the same STS criteria across investigations.

In contrast to DIHL study listings, none of the NIHL, stable SNHL, or acute SSNHL trials reported ASHA SOC, CTCAE adverse hearing events, or any of the other categorical ototoxicity monitoring scales as clinical trial outcomes. As discussed in Le Prell et al, one could envision the rate of OSHA STS (an average threshold shift of 10 dB or greater at 2, 3 and 4 kHz) being monitored in occupational NIHL prevention studies. However, as discussed in that report, using the median age-corrected NIHL data from ISO-1999 data, the median worker with 90 dBA time-weighted-average (TWA) exposure (90 dBA for 8 hrs or other exposure accruing 100% dose) would be predicted to develop an OSHA STS at approximately 20 years of exposure. Little additional STS growth would be predicted for the median worker over the next 20 years of occupational exposure given that NIHL is decelerating (accrues more quickly in early years, more slowly in later years) whereas ARHL is accelerating (accrues slowly in early years, more quickly in later years). This has tremendous implications for NIHL prevention study feasibility as it suggests that workers would need to be enrolled early in their occupational career and followed for extended periods of time to adequately power a clinical trial assessing prevention of OSHA STS in workers who wear HPDs that effectively reduce their exposure to 100% of the permissible exposure limit (90 dBA TWA). However, best practice is to attenuate exposure to less than 85 dBA TWA. If exposure is effectively attenuated to 85 dBA TWA across the working career, the ISO-1999 data suggest that the median worker would develop 5 dB noise-induced PTS averaged at 2, 3, and 4 kHz after 40 years of exposure. Because workers do not routinely achieve the expected level of protection from HPDs, it is possible that hearing loss would accrue more quickly and to a greater degree if workers were followed over time as part of a clinical trial. However, it is also possible that HPD use might improve due to the workers attention to their hearing as part of enrollment in the clinical trial. It is difficult to provide guidance on PTS prevention study designs given the emphasis on TTS prevention within the existing study listings and limited rate of PTS in the single Phase 3 study listed. Additional detailed discussion of the state of the science for NIHL otoprotection research based on both the peer-reviewed literature and studies listed in ClinicalTrials.gov can be found in Le Prell.

Looking beyond the audiogram, DPOAEs were monitored in about 33% of the DIHL and 56% of the NIHL trials, but they were largely absent from stable SNHL and acute SSNHL clinical trials. In participants entering a clinical trial with significant hearing loss, as in many of the stable SNHL and acute SSNHL trials in Tables 3 and 4, DPOAEs likely have limited utility as they are expected to be compromised at enrollment and thus it is not surprising they were not included in the study test battery. In NIHL and DIHL prevention studies, the participants are likely to have hearing that is within normal limits at the time of enrollment and thus changes in DPOAEs can be monitored for insights into OHC loss prior to the development of threshold shift.

Conversely, word recognition in quiet was monitored in 44-46% of the stable SNHL and acute SSNHL clinical trials but none of the NIHL trials and only 7% of the DIHL trials. Given that hearing-in-noise is compromised the day after recreational noise exposure even in the absence of TTS and there is significant evidence of hearing-in-noise difficulties in groups of participants with significant noise exposure compared to control groups with less sound exposure, one might predict hearing-in-noise measures would be commonly included in NIHL otoprotection research. Despite documented noise-induced deficits, hearing in noise is not commonly used in clinical trials assessing NIHL prevention. Patient complaints regarding hearing-in-noise difficulties were a topic of discussion at the recent Hearing Loss Association of America (HLAA) meeting on investigational medicines for the inner ear, titled, “Externally-led patient-focused drug development (PFDD) meeting for people and families living with sensorineural hearing loss” (https://www.hearingloss.org/haa-pfdd/). PFDD meetings are FDA-led public meetings through which patients and their families provide input to the FDA regarding their most significant symptoms, impact of the condition on daily life, and current approaches to treatment. It is possible that these patient commentaries will prompt greater attention to hearing in noise measurements when evaluating drug benefits.

Finally, while DIHL is often accompanied by comorbidities including tinnitus and balance disorders, only 23% of DIHL clinical trials included tinnitus metrics whereas 56% of the NIHL otoprotection studies included tinnitus metrics. Where validated surveys have been used, the THI and TFI have been the two most frequently used surveys; however, in many cases the ClinicalTrials.gov listing did not specify a formal tinnitus survey. This is a known shortcoming of the ClinicalTrials.gov database. The instructions suggest but do not
require a detailed protocol. Therefore, while the outcomes are listed, how those outcomes will be collected is not always clear, limiting the ability to replicate clinical trial design using only the ClinicalTrials.gov listing. To know what equipment was used, what transducers were used, who collected the data, what the presentation levels for the speech materials were, the order of test administration, etc., one would need to wait for information to (hopefully) be provided within the peer-reviewed literature or communicate with the study contact listed on ClinicalTrials.gov in hopes they will share more information. Abrams et al. provide comprehensive discussion of these issues and recommendations for increased transparency including through the advance (pre-study) publication of protocols.

In closing, the information captured in this review highlights the tremendous progress that has been made, with work transitioning from animal models to clinical trials, and reviews the studies that are described within ClinicalTrials.gov for four specific inner ear indications: NIHL, DIHL, stable SNHL, and acute SSNHL. The results summarized in this report should be interpreted carefully given that data are limited to the ClinicalTrials.gov records and thus the results do not broadly reflect international activity but rather are primarily a reflection of US research. However, given that drugs being developed for possible future approval in the US are typically developed through the IND process, and regulatory statutes state that clinical trials reviewed through the IND process must be listed on ClinicalTrials.gov, it seems reasonable to conclude that without a healthy pipeline of clinical trial listings in the ClinicalTrials.gov database, there will not be a healthy pipeline of drugs progressing through the FDA review process for possible future human use preventing or treating human acquired hearing loss. The information provided in this report provides insights into the audiometric outcomes that have been selected in clinical trials and which can be considered for use by those who are planning new clinical trials evaluating investigational medicinal products for the inner ear.

**Summary and Conclusion**

42 CFR Part 11 requires clinical trials initiated after September 27, 2007 to be listed in the ClinicalTrials.gov database if they meet certain criteria regarding collection of data at U.S. study sites or if the drugs being used in the clinical trial are manufactured in and exported from the U.S. The current search of this database for information on clinical trials evaluating investigational medicinal products for the inner ear therefore provides new insights into 1) variation in the clinical trial populations in which drug interventions are currently being evaluated or have been evaluated within the past 15 years, and 2) variation in clinical trial outcomes across NIHL and DIHL otoprotection trials as well as drug intervention studies for stable SNHL and acute SSNHL. Drugs evaluated for these different targets have varied across indications despite the shared otopathology underlying many of these clinical targets. While the audiogram has often served as a primary outcome, average threshold shift has been the predominant outcome in NIHL, SNHL, and SSNHL trials whereas the rate of STS has been the predominant outcome in DIHL trials. Secondary and other outcomes have varied with respect to use of DPOAEs, extended high frequency hearing, word recognition in quiet, hearing in noise, tinnitus, and use of quality of hearing/quality of life surveys to assess global patient outcomes. The current review provides increased transparency into the variation across study designs. Increased consistency in the selection of primary and secondary outcomes within indications would facilitate comparisons of efficacy across investigational medicinal products. Different test batteries are needed for different inner ear indications based on patient/participant hearing ability, expected progression of deficits over time, and treatment goals.

**Funding/Disclosure**

CL is currently supported by USAMRAA W81XWH-19-C-0054, JPC-8/SRMWP W81XWH1820014, NIH-NIDCD 1R01DC014088, 3M Inc., and the Emilie and Phil Schepps Professorship in Hearing Science. CL has previously received contract funding and/or clinical trial material from industry partners including Sound Pharmaceuticals, Inc., Edison Pharmaceuticals, Inc., and Hearing Health Science, Inc. The views expressed in this article are those of the author and do not reflect the official policy or position of the Department of the Army, Department of the Defense, or the U.S. Government.

**Conflict of Interest**

None declared.

**Disclaimer**

Any mention of a product, service, or procedure in the *Journal of the American Academy of Audiology* does not constitute an endorsement of the product, service, or procedure by the American Academy of Audiology.

**References**

1. Hawkins JE, Schacht J. Sketches of otohistory. Part 10: Noise-induced hearing loss. Audiol Neurotol 2005;10(06):305–309
2. Schacht J, Hawkins JE. Sketches of otohistory. Part 9: Presbycusis. Audiol Neurotol 2005;10(05):243–247
3. Schacht J, Hawkins JE. Sketches of otohistory. Part 11: Ototoxicity: drug-induced hearing loss. Audiol Neurotol 2006;11(01):1–6
4. Dinis-Oliveira RJ, Sousa C, Remião F, et al. Full survival of paraquat-exposed rats after treatment with sodium salicylate. Free Radic Biol Med 2007;42(07):1017–1028
5. Kujawa SG, Liberman MC. Translating animal models to human therapeutics in noise-induced and age-related hearing loss. Hear Res 2019;377:44–52
6. Bramhall N, Beach EF, Epp B, et al. The search for noise-induced cochlear synaptopathy in humans: Mission impossible? Hear Res 2019;377:88–103
7. Le Prell CG. Effects of noise exposure on auditory brainstem response and speech-in-noise tasks: A review of the literature. Int J Audiol 2019a;58(Suppl 1):S3–S32
8. Parker MA. Identifying three otopathologies in humans. Hear Res 2020;398:108079
9. Henderson D, Bielefeld EC, Harris KC, Hu BH. The role of oxidative stress in noise-induced hearing loss. Ear Hear 2006;27(01):1–19
10 Le Prell CG, Yamashita D, Minami SB, Yamasoba T, Miller JM. Mechanisms of noise-induced hearing loss indicate multiple methods of prevention. Hear Res 2007;226(1-2):22–43
11 Abi-Hachem RN, Zine A, Van De Water TR. The injured cochlea as a target for inflammatory processes, initiation of cell death pathways and application of related otoprotective strategies. Recent Patents CNS Drug Discov 2010;5(02):147–163
12 Poirier AL, Pincemail J, Van Den Ackerveken P, et al. Oxidative stress in the cochlea: An update. Curr Med Chem 2010;17(30):3591–3604
13 Oishi N, Schacht J. Emerging treatments for noise-induced hearing loss. Expert Opin Emerg Drugs 2011;16(02):235–245
14 Le Prell CG, Bao J. 2012 Prevention of noise-induced hearing loss: potential therapeutic agents. In: Le Prell CG, Henderson D, Fay RR, Popper AN, eds. Noise-Induced Hearing Loss: Scientific Advances, Springer Handbook of Auditory Research. Springer Science + Business Media, LLC New York
15 Trew M, Lobarinas E, Lea J, Westerberg B. Current insights in noise-induced hearing loss: A literature review of the underlying mechanism, pathophysiology, asymmetry, and management options. J Otolaryngol Head Neck Surg 2017;46(01):41
16 Sha SH, Schacht J. Emerging therapeutic interventions against noise-induced hearing loss. Expert Opin Investig Drugs 2017;26(01):85–96
17 Hammill TL, Campbell KC. Protection for medication-induced hearing loss: The state of the science. Int J Audiol 2018;57(sup4):S67–S75
18 Le Prell CG. Otoprotectants: From research to clinical application. Semin Hear 2019b;40(02):162–176
19 Schilder ACM, Su MP, Blackshaw H, et al. Hearing protection, restoration, and regeneration: An overview of emerging therapeutics for inner ear and central hearing disorders. Otol Neurotol 2019;40(05):539–570
20 Wang J, Puel JL. Presbycusis: An update on cochlear mechanisms and therapies. J Clin Med 2020;9(01):9
21 Gupta A, Koochakzadeh S, Nguyen SA, et al. Pharmacological prevention of noise-induced hearing loss: A systematic review. Otol Neurotol 2021;42(01):2–9
22 Le Prell CG, Miller JM. 2016 The role of oxidative stress in hearing loss. In: Armstrong D, Stratton RD, eds. Oxidative Stress and Antioxidant Protection: The Science of Free Radical Biology & Disease. John Wiley & Sons, Inc. New Jersey
23 Ohlemiller KK. Mouse methods and models for studies in hearing. J Acoust Soc Am 2019;146(05):3688–3680
24 Escabi CD, Frye MD, Trew M, Lobarinas E. The rat animal model for noise-induced hearing loss. J Acoust Soc Am 2019;146(05):3692–3709
25 Holt AG, Kühl A, Braun RD, Altschuler R. The rat as a model for studying noise injury and ototoxicity. J Acoust Soc Am 2019;146(05):3681–3691
26 Naert G, Pasdelou M-P, Le Prell CG. Use of the guinea pig in studies on the development and prevention of acquired sensori-neural hearing loss, with an emphasis on noise. J Acoust Soc Am 2019;146(05):3743–3769
27 Trevino M, Lobarinas E, Maulden AC, Heinz MG. The chinchilla animal model for hearing science and noise-induced hearing loss. J Acoust Soc Am 2019;146(05):3710–3732
28 Radziwon KE, Sheppard A, Salvi RJ. Psychophysical changes in temporal processing in chinchillas with noise-induced hearing loss: A literature review. J Acoust Soc Am 2019;146(05):3733–3742
29 Bielefeld EC, Harrison RT, DeBacker RJ. Pharmaceutical otoprotection strategies to prevent impulse noise-induced hearing loss. J Acoust Soc Am 2019;146(05):3790–3799
30 Gittelman SN, Le Prell CG, Hammill TL. Octave band noise exposure: Laboratory models and otoprotection efforts. J Acoust Soc Am 2019;146(05):3800–3810
31 Zhang J. Blast-induced tinnitus: Animal models. J Acoust Soc Am 2019;146(05):3811
32 Le Prell CG, Lobarinas E. 2015 Strategies for assessing antioxidant efficacy in clinical trials. In: Miller JM, Le Prell CG, Rybak LP, eds. Oxidative Stress in Applied Basic Research and Clinical Practice: Free Radicals in ENT Pathology. Humana Press New York
33 Konrad-Martín D, Poling GL, Dreisbach LE, et al. Serial monitoring of otoacoustic emissions in clinical trials. Otol Neurotol 2016;37(08):e286–e294
34 Le Prell CG, Brungart DS. Speech-in-noise tests and supra-threshold auditory evoked potentials as metrics for noise damage and clinical trial outcome measures. Otol Neurotol 2016;37(08):e295–e302
35 Le Prell CG, Campbell KCM. 2020 Clinical test paradigms and problems: Human otoprotection studies. In: Hatzopoulos S, Ciorba A, Krumm M, eds. Advances in Audiology, Speech Pathology, and Hearing Science, Volume 2: Otoprotection, Regeneration and Telemedicine. Apple Academic Press New Jersey
36 Lynch ED, Kil J, Le Prell CG. 2016 Human clinical studies in noise-induced hearing loss. In: Le Prell CG, Lobarinas E, Fay RR, Popper AN, eds. Translational Research in Audiology and the Hearing Sciences, Springer Handbook of Auditory Research. Springer New York
37 Hecht QA, Hammill TL, Calamia PT, et al. Characterization of acute hearing changes in United States military populations. J Acoust Soc Am 2019;146(05):3839–3848
38 Wartinger F, Malyuk H, Portnuff CDF. Human exposures and their associated hearing loss profiles: Music industry professionals. J Acoust Soc Am 2019;146(05):3906–3910
39 Le Prell CG, Hammill TL, Murphy WJ. Noise-induced hearing loss and its prevention: Integration of data from animal models and human clinical trials. J Acoust Soc Am 2019;146(05):4051–4074
40 Themann C, Masterson EA. Occupational noise exposure: A review of its effects, epidemiology, and impact with recommendations for reducing its burden. J Acoust Soc Am 2019;146(05):3879
41 Anderson JM, Campbell K. 2015 Assessment of interventions to prevent drug-induced hearing loss. In: Miller JM, Le Prell CG, Rybak LP, eds. Oxidative Stress in Applied Basic Research and Clinical Practice: Free Radicals in ENT Pathology. Humana Press New York
42 Campbell KCM, Fox DJ. 2016 Cisplatin-induced hearing loss. In: Le Prell CG, Lobarinas E, Fay RR, Popper AN, eds. Translational Research in Audiology and the Hearing Sciences, Springer Handbook of Auditory Research. Springer New York
43 American Academy of Audiology. 2009 Position statement and clinical practice guidelines: Otoxicity monitoring: Last accessed July 12, 2021. https://audiology-web.s3.amazonaws.com/migrated/OtoMonGuidelines.pdf_539974c40999c1.58842217.pdf
44 American Speech-Language-Hearing Association. Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy. ASHA 1994;36(Suppl 12):11–19
45 King KA, Brewer CC. Clinical trials, ototoxicity grading scales and the audiologist’s role in therapeutic decision making. Int J Audiol 2018;57(sup4):S89–S98
46 Konrad-Martín D, James KE, Gordon JS, et al. Evaluation of audiometric threshold shift criteria for ototoxicity monitoring. J Am Acad Audiol 2010;21(05):301–314, quiz 357
47 Vetter TR, Mascha EJ. Defining the primary outcomes and justifying secondary outcomes of a study: Usually, the fewer, the better. Anesth Analg 2017;125(02):678–681
48 De Angelis CD, Drazen JM, Frizelle FA, et al; International Committee of Medical Journal Editors. Is this clinical trial fully registered? – A statement from the International Committee of Medical Journal Editors N Engl J Med 2005b352(23):2436–2438
49 De Angelis CD, Drazen JM, Frizelle FA, et al; International Committee of Medical Journal Editors. Is this clinical trial fully registered? A statement from the International Committee of Medical Journal Editors. Lancet2005a365(9474):1827–1829
NCT00552786 (Last update, July 27, 2010) Antioxidation Mediation for Noise-induced Hearing Loss. Retrieved December 29, 2020 from http://clinicaltrials.gov/ct2/show/NCT00552786

NCT00808470 (Last update, May 19, 2017) Micronutrients to Prevent Noise-induced Hearing Loss. Retrieved December 29, 2020 from http://clinicaltrials.gov/ct2/show/NCT00808470

NCT01444846 (Last update, August 28, 2014) Otoprotection With SPI-1005. Retrieved December 29, 2020 from http://clinicaltrials.gov/ct2/show/NCT01444846

NCT02257983 (Last update, November 18, 2020) Protective effects of ER-743 on noise-induced hearing loss. Retrieved December 29, 2020 from http://clinicaltrials.gov/ct2/show/NCT02257983

NCT02903355 (Last update, April 29, 2019) Phase 3 Clinical Trial: D-Methionine to Reduce Noise-Induced Hearing Loss (NIHL). Retrieved December 22, 2020 from https://clinicaltrials.gov/ct2/show/NCT02903355

NCT02779192 (Last update, August 24, 2018) A Phase 2b Study of SPI-1005 to Prevent Acute Noise Induced Hearing Loss (PANIHL). Retrieved December 29, 2020 from https://clinicaltrials.gov/ct2/show/NCT02779192

NCT01727492 (Last update, November 6, 2013) Prevention of Noise-induced Damage by Use of Antioxidants. Retrieved February 21, 2021 from http://clinicaltrials.gov/ct2/show/NCT01727492

NCT02049073 (Last update, November 6, 2017) Prevention of Noise-induced Hearing Loss. Retrieved December 29, 2020 from http://clinicaltrials.gov/ct2/show/NCT02049073

NCT04768569 (Last update, February 24, 2021) Noise-Induced Hearing Loss-Acute Exposure Treatment (PINIHL-AET). Retrieved June 11, 2021 from https://clinicaltrials.gov/ct2/show/NCT04768569

NCT04774250 (Last update, March 1, 2021) Noise-Induced Hearing Loss-Acute Exposure Treatment (UA)(PINIHL-AET). Retrieved June 11, 2021 from https://clinicaltrials.gov/ct2/show/NCT04774250

NCT00003269 (Last update, January 10, 2011) Amyostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors. Retrieved February 16, 2021 from https://clinicaltrials.gov/ct2/show/NCT00003269

NCT00477607 (Last update, March 7, 2014) Alpha-Lipoic Acid in Preventing Hearing Loss in Cancer Patients Undergoing Treatment With Cisplatin. Retrieved February 16, 2021 from https://clinicaltrials.gov/ct2/show/NCT00477607

NCT00652132 (Last update, May 29, 2018) Cisplatin With or Without Sodium Thiosulfate in Treating Young Patients With Stage I, II, or III Childhood Liver Cancer (SIOPEL6). Retrieved February 18, 2021 from https://clinicaltrials.gov/ct2/show/NCT00652132

NCT00716976 (Last update, September 20, 2018) Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy. Retrieved February 18, 2021 from https://clinicaltrials.gov/ct2/show/NCT00716976

NCT01139281 (Last update, June 8, 2010) The Protective Effect of Ginkgo Biloba Extract on Cisplatin-induced Ototoxicity in Humans. Retrieved February 16, 2021 from https://clinicaltrials.gov/ct2/show/NCT01139281

NCT01372904 (Last update, July 17, 2014) Prevention of Cisplatin-Induced Hearing Loss by Intratympanic Dexamethasone Treatment. Retrieved February 18, 2021 from https://clinicaltrials.gov/ct2/show/NCT01372904

NCT01848457 (Last update, March 16, 2020) Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy. Retrieved February 16, 2021 from https://clinicaltrials.gov/ct2/show/NCT01848457

NCT03400709 (Last update, January 17, 2018) Protective Role of N-acetylcysteine From Cisplatin-induced Ototoxicity in Patients With Head and Neck Cancer. Retrieved February 18, 2021 from https://clinicaltrials.gov/ct2/show/NCT03400709

NCT01131468 (Last update, May 27, 2010) Prevention of Drug Induced Ototoxicity in Peritoneal Dialysis Patients by N-Acetylcysteine. Retrieved February 18, 2021 from https://clinicaltrials.gov/ct2/show/NCT01131468

NCT01271088 (Last update, November 16, 2011) Protective Effect of N-acetylcysteine Against From Ototoxicity. Retrieved February 16, 2021 from https://clinicaltrials.gov/ct2/show/NCT01271088

NCT02094625 (Last update, June 23, 2020) NAC to Prevent Cisplatin-induced Hearing Loss. Retrieved February 18, 2021 from https://clinicaltrials.gov/ct2/show/NCT02094625

NCT04262336 (Last update, July 21, 2020) Study to Evaluate Safety and Efficacy of DB-020 to Protect Hearing in Patients Receiving Cisplatin for Cancer Treatment. Retrieved February 18, 2021 from https://clinicaltrials.gov/ct2/show/NCT04262336

NCT04291209 (Last update, March 2, 2020) Intratympanic N-Acetylcysteine for Prevention of Cisplatin-induced Ototoxicity. Retrieved February 18, 2021 from https://clinicaltrials.gov/ct2/show/NCT04291209

NCT04541355 (Last update, October 20, 2020) Sodium Thiosulfate for the Prevention of Ototoxicity in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck Undergoing Chemoradiation With Cisplatin. Retrieved February 18, 2021 from https://clinicaltrials.gov/ct2/show/NCT04541355

NCT04226456 (Last update, February 9, 2021) Intratympanic Administration of N-acetylcysteine for Protection of Cisplatin-induced Ototoxicity. Retrieved February 21, 2021 from https://clinicaltrials.gov/ct2/show/NCT04226456

NCT00075387 (Last update, November 10, 2020) Combination Chemotherapy With or Without Sodium Thiosulfate in Preventing Low Platelet Count While Treating Patients With Malignant Brain Tumors. Retrieved February 19, 2021 from https://clinicaltrials.gov/ct2/show/NCT00075387

NCT00983398 (Last update, September 17, 2020) Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors. Retrieved February 18, 2021 from https://clinicaltrials.gov/ct2/show/NCT00983398

NCT02819856 (Last update, March 19, 2019) SPI-1005 for Prevention and Treatment of Aminoglycoside Induced Ototoxicity. Retrieved February 16, 2021 from https://clinicaltrials.gov/ct2/show/NCT02819856

NCT00074165 (Last update, April 21, 2017) Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen. Retrieved February 18, 2021 from https://clinicaltrials.gov/ct2/show/NCT00074165

NCT01369641 (Last update, October 18, 2017) The Effect of Sodium Thiosulfate Eardrops on Hearing Loss in Patients Who Receive Cisplatin Therapy. Retrieved February 18, 2021 from https://www.clinicaltrials.gov/ct2/show/NCT01369641

NCT02281006 (Last update, January 27, 2017) Efficacy of Transytympanic Injections of a Sodium Thiosulfate Gel to Prevent Cisplatin-induced Ototoxicity (ST5001). Retrieved February 18, 2021 from https://clinicaltrials.gov/ct2/show/NCT02281006

NCT02997189 (Last update, September 16, 2020) Safety and Efficacy of SPI-1005 In Subjects at Risk From Cisplatin-Induced Hearing Loss. Retrieved February 18, 2021 from https://clinicaltrials.gov/ct2/show/NCT02997189

NCT01138137 (Last update, April 21, 2017) N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer. Retrieved February 18, 2021 from https://clinicaltrials.gov/ct2/show/NCT01138137

NCT00584155 (Last update, May 27, 2015) Protection From Cisplatin Ototoxicity by Lactated Ringers. Retrieved February 18, 2021 from https://clinicaltrials.gov/ct2/show/NCT00584155

NCT02382068 (Last update, November 9, 2017) Dexamethasone in Preventing Hearing Loss in Patients Receiving Cisplatin. Retrieved February 18, 2021 from https://clinicaltrials.gov/ct2/show/NCT02382068
124 Jokel C, Yankaskas K, Robinette MB. Noise of military weapons, ground vehicles, planes and ships. J Acoust Soc Am 2019;146 (05):3832–3838
125 Neitzel RL, Fligor BJ. Risk of noise-induced hearing loss due to recreational sound: Review and recommendations. J Acoust Soc Am 2019;146(05):3911–3921
126 Roberts B, Neitzel RL. Noise exposure limit for children in recreational settings: Review of available evidence. J Acoust Soc Am 2019;146(05):3922–3933
127 OSHA. 1983 CFR 1910.95. Occupational Noise Exposure; Hearing Conservation Amendment; Final Rule, effective 8 March 1983.
128 International Standard Organization. 2013 Acoustics: Estimation of noise-induced hearing loss (ISO-1999). International Standard OrganizationGeneva, Switzerland
129 NIOSH. 1998 Criteria for a Recommended Standard, Occupational Noise Exposure, DHHS (NIOSH) Publication No.98–126. DHHS/CDC/NIOSH, Cincinnati, OH.
130 Le Prell CG. Prevention of noise-induced hearing loss using investigational medicines for the inner ear: Previous trial outcomes should inform future trial design. Antioxid Redox Signal in press
131 Grinn SK, Wiseman KB, Baker JA, Le Prell CG. Hidden hearing loss? No effect of common recreational noise exposure on cochlear nerve response amplitude in humans. Front Neurosci 2017;11:465
132 Le Prell CG, Clavier OH. Effects of noise on speech recognition: Challenges for communication by service members. Hear Res 2017;349:76–89
133 Abrams HB, Chisolm TH, Sanchez VA, et al. Guest editorial: Background and rationale for clinical trial registration. Ear Hear 2018;39(02):191–196